Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation

Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation Riti Sharan, Yi Zou, Zhao Lai, Bindu Singh, Vinay Shivanna, Edward Dick, Jr, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4908400/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Dec, 2025 Read the published version in Nature Communications → Version 1 posted You are reading this latest preprint version Abstract The majority of Human Immunodeficiency Virus (HIV) negative individuals exposed to Mycobacterium tuberculosis ( Mtb ) control the bacillary infection as latent TB infection (LTBI). Co-infection with HIV, however, drastically increases the risk to progression to tuberculosis (TB) disease. TB is therefore the leading cause of death in people living with HIV (PLWH) globally. Combinatorial antiretroviral therapy (cART) is the cornerstone of HIV care in humans and reduces the risk of reactivation of LTBI. However, the immune control of Mtb infection is not fully restored by cART as indicated by higher incidence of TB in PLWH despite cART. In the macaque model of co-infection, skewed pulmonary CD4 + T EM responses persist, and new TB lesions form despite cART treatment. We hypothesized that regimens that concurrently administer anti-TB therapy and cART would significantly reduce TB in co-infected macaques than cART alone, resulting in superior bacterial control, mitigation of persistent inflammation and lasting protective immunity. We studied components of TB immunity that remain impaired after cART in the lung compartment, versus those that are restored by concurrent 3 months of once weekly isoniazid and rifapentine (3HP) and cART in the rhesus macaque (RM) model of LTBI and Simian Immunodeficiency Virus (SIV) co-infection. Concurrent administration of cART + 3HP did improve clinical and microbiological attributes of Mtb /SIV co-infection compared to cART-naïve or -untreated RMs. While RMs in the cART + 3HP group exhibited significantly lower granuloma volumes after treatment, they, however, continued to harbor caseous granulomas with increased FDG uptake. cART only partially restores the constitution of CD4 + T cells to the lung compartment in co-infected macaques. Concurrent therapy did not further enhance the frequency of reconstituted CD4 + T cells in BAL and lung of Mtb /SIV co-infected RMs compared to cART, and treated animals continued to display incomplete reconstitution to the lung. Furthermore, the reconstituted CD4 + T cells in BAL and lung of cART + 3HP treated RMs exhibited an increased frequencies of activated, exhausted and inflamed phenotype compared to LTBI RMs. cART + 3HP failed to restore the effector memory CD4 + T cell population that was significantly reduced in pulmonary compartment post SIV co-infection. Concurrent therapy was associated with the induction of Type I IFN transcriptional signatures and led to increased Mtb -specific T H1 /T H17 responses correlated with protection, but decreased Mtb -specific TNFa responses, which could have a detrimental impact on long term protection. Our results suggest the mechanisms by which Mtb /HIV co-infected individuals remain at risk for progression due to subsequent infections or reactivation due of persisting defects in pulmonary T cell responses. By identifying lung-specific immune components in this model, it is possible to pinpoint the pathways that can be targeted for host-directed adjunctive therapies for TB/HIV co-infection. Health sciences/Diseases/Infectious diseases/Tuberculosis Biological sciences/Immunology/Infectious diseases/HIV infections cART 3HP TB/SIV co-infection LTBI reactivation Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Combinatorial antiretroviral therapy (cART) reduces the risk of reactivation of latent tuberculosis infection (LTBI) in humans [ 1 – 4 ]. However, tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLWH) [ 5 – 7 ]. Anti-tubercular treatment has been shown to reduce disease incidence by 30–50%[ 8 , 9 ] and is recommended for PLWH in high-burden countries. Observational studies in humans suggest that concurrent administration of cART and Isoniazid Preventive Therapy (IPT) for LTBI lowers the risk of developing TB compared to cART alone [ 10 ]. A randomized double-blind placebo-controlled trial [ 8 ] showed that administering IPT in conjunction with cART resulted in significantly lower numbers of incident TB cases than cART plus placebo. Thus, concurrent cART + IPT leads to improved outcomes with clear protective effects and clinical benefit to HIV-infected individuals. Although the WHO recommends concurrent IPT and cART in TB-endemic settings, uptake remains poor and the immune mechanisms underlying the benefits of concurrent cART and IPT have not been defined. Another caveat of this approach has been a lack of completion of treatment regimen by majority of those who initiate the 6-month course of daily isoniazid while on cART. To enable treatment adherence and completion, the World Health Organization (WHO) recommended 12-dose weekly regimen of Isoniazid and Rifapentine (3HP) as a treatment-shortened option for treating TB. Concurrent administration of cART and 3HP was safe and well tolerated with over 95% completion rate [ 11 , 12 ]. In our RM model of Mycobacterium tuberculosis ( Mtb) /SIV co-infection, though 3HP effectively reduced persistent LTBI [ 12 ], it did not sterilize the lungs of a third of the treated RMs [ 13 ]. Recent work in Mtb /SIV co-infected RMs [ 14 ] shows that in addition to the depletion of CD4 + T cells, HIV-driven chronic immune activation correlates with LTBI reactivation [ 14 – 18 ]. Though cART controls viral replication, it leads to insufficient reconstitution of protective CD4 + T effector memory (T EM ) responses in the lungs [ 15 ] and fails to rescue from virus-driven immune activation [ 19 ]. Administration of anti-tubercular therapy, concurrently with cART reduces reactivation significantly better than cART among individuals with LTBI [ 11 ]. However, long-term sterilization of bacteria and immune reconstitution in the lungs has not been shown in these individuals. In this study, we leveraged our nonhuman primate (NHP) model of Mtb /SIV co-infection to study effect of simultaneous cART and 3HP treatment on immune responses to Mtb . Performing these studies in humans is virtually impossible due to lack of determination of timing of Mtb and HIV co-infections, verification of bacterial and viral loads and performance of invasive longitudinal studies to investigate the lung compartment. Our very low-dose aerosol infection NHP model recapitulates the spectrum of human lung pathological lesions, including LTBI and its reactivation to active TB by HIV [ 13 – 15 , 17 , 20 ]. We carried out detailed studies of the immune responses by longitudinal sampling of blood and bronchoalveolar lavage (BAL) in the absence of cART as well as during and after cART and cART + 3HP. Importantly, we investigated the functional capacity of antigen-specific T cell immunity in the lung microenvironment. Our findings clearly show that while cART and 3HP control viral and bacterial replication, respectively, there is partial immune reconstitution and with the reconstituted CD4 + T cell exhibited highly impaired functional capabilities. In particular, skewed CD4 + T effector memory responses persist despite concurrent cART and anti-TB treatment in Mtb /SIV co-infected macaques and the ongoing inflammation in the lung is not ameliorated. It is well known that PLHIV and TB remain at risk for progression due to subsequent infections or TB reactivation even after improved clinical and microbiological attributes. We conclude that persisting immune activation/inflammation are the mechanisms that cause this susceptibility. Clearly host directed therapies against immune activation and lung inflammation, adjunctive to TB therapy and cART must be developed to better treat PLHIV with TB. Results Concurrent treatment with cART and 3HP improves clinical and microbiological attributes of Mtb/SIV co-infection . To assess the impact of concurrent cART and 3HP therapy on LTBI reactivation in Mtb /SIV co-infection, we utilized 6 new RMs and reused published data from LTBI ( n = 4), cART -naïve coinfected RMs ( n = 8) and co-infected RMs treated with cART alone for 9 weeks ( n = 4) (refs 15, 19 and Supplemental Table 2). The study design is outlined in Fig. 1 A. All the RMs were infected with a low dose of Mtb (~ 10 CFU deposited in the lungs) and subsequently with SIV (300 TCID 50 SIV mac239 , intravenous). Infection was confirmed by a positive tuberculin skin test at weeks 3 and 5 after Mtb infection. All study RMs developed LTBI infection characterized by less than 1 to 2 Log 10 CFU of Mtb in the bronchoalveolar lavage (BAL) at weeks 3, 5 and 7 post Mtb infection, serum C-reactive protein (CRP) of 5 µg/mL or lower (Fig. 1 B), and no significant change in percentage body temperature (Supplemental Fig. 1A) and body weight (Supplemental Fig. 1B) up to 9 weeks after Mtb infection. Upon establishment of latency, RMs were coinfected with 300 TCID 50 SIV mac239 via the intravenous route 9 weeks after Mtb infection [ 14 , 15 , 20 ]. SIV infection was confirmed by measuring the plasma viral loads via reverse transcriptase quantitative PCR (RT-qPCR). The RMs were either treated with cART alone or cART + 3HP, once weekly orally for 12 weeks (Fig. 1 A) and euthanized at treatment completion. Clinical, pathological and immunological response was compared in the 4 experimental groups: LTBI, cART naïve, cART and cART + 3HP. The RMs in cART + 3HP group survived in good body condition with adequate body muscling and fat until the predetermined study endpoint. RMs in cART naïve group were humanely euthanized on prespecified endpoints starting as early as 2 weeks post SIV co-infection (Supplemental Fig. 1C). Elevated serum CRP levels associate with active TB and increase in bacterial burdens in NHPs [ 15 , 17 , 20 ]. CRP levels in cART + 3HP were significantly lower than cART naïve ( P < 0.0001 ) and cART treated RMs ( P < 0.001 ) (Fig. 1 B). More importantly, the CRP levels in cART + 3HP RMs was not significantly different from LTBI RMs ( P = 0.44). To determine the impact of cART + 3HP on bacterial burden, BAL fluid, lungs, bronchial lymph nodes and lung granulomas were plated on 7H11 agar plates as previously described [ 14 , 15 , 17 , 20 ]. 5 out of 6 RMs in cART + 3HP group had no detectable bacterial burden in lung collected at necropsy, compared to just 1 out of four cART-treated and 2 out of 14 cART-naive RMs and both differences were statistically significant (Fig. 1 C). Thus, the cART + 3HP group behaved comparable to the LTBI (SIV uninfected) group with 87.5% and 75% of the lung samples being sterile respectively in these groups. All 6 RMs in cART + 3HP group were devoid of detectable bacilli in lung granulomas (Fig. 1 D), BAL (Fig. 1 E) and bronchial lymph nodes (Fig. 1 F) at necropsy. Additionally, the bacterial burden in cART + 3HP RMs was significantly lower than cART treated RMs in lung ( P = 0.01 ), lung granulomas ( P = 0.001 ) and bronchial lymph node ( P < 0.0001 ). In contrast 81% RMs harbored bacilli in lung granulomas and 100% of study animals had detectable bacilli in bronchial lymph nodes when treated with cART alone (Fig. 1 D and 1 F). To evaluate the efficacy of cART regimen in presence of 3HP treatment, viral loads were measured in the plasma of all 6 RMs and compared with cART treated RMs at pre-determined time points post cART initiation (Fig. 1 G). There was no significant difference in the rates of decay of the viral loads in either group. Thus, 3HP did not alter the efficacy of cART in controlling viral replication. We also studied cytotoxicity markers in blood to determine safety of administering cART + 3HP relative to untreated and 3HP treated cohorts from archived samples. We did not observe any significant change in the levels of serum albumin/globulin (A/G) (g/dL) ratio, aspartate aminotransferase or serum glutamic-oxaloacetic transaminase (ALT/SGOT) (units per liter of serum), blood urea nitrogen/creatinine (BUN/creat) (µmol/L) ratio, and alkaline phosphatase (Alk phos) (units per liter), at week 24 after TB infection or 1 – week after treatment completion (Fig. 1 H) in untreated, 3HP treated and cART + 3HP treated RMs. To determine the impact of cART + 3HP treatment on the lung cellular and granulomatous pathology, lung tissue sections collected at necropsy were stained with hematoxylin and eosin (H&E) (Fig. 1 I) and findings analyzed by board-certified (Dipl, American College of Veterinary Pathologists) pathologists. The pathological findings correlated with the clinical and microbiological observations. There were a few, scattered, non-necrotizing and caseous granulomas in the lung lobes of approximately 0.5–1 cm in size in cART + 3HP treated RMs. There were rare, small aggregates of lymphocytes and macrophages in some lung sections. A single RM demonstrated multifocal accumulations of lymphocytes and non-necrotizing active granulomas in the liver. Overall, hilar, bronchial lymph nodes, spleen and other tissues were observed to have normal pathology comparable to LTBI only controls. cART + 3HP RMs demonstrated significant decrease in percentage lung involvement in pathology compared to cART and cART naïve RMs (Fig. 1 J). Overall, lung of cART + 3HP treated RMs harbored less lesions compared to cART-naïve RMs. Lung of cART naïve and cART alone treated RMs showed numerous large granulomas with necrotic cores. Thus, administration of cART + 3HP is safe, efficacious in controlling bacterial burden and improved pathology compared to cART treated RMs. We performed Positron Emission Tomography with Computed Tomography (PET/CT) to study lung lesions in 3 of the 6 RMs at weeks 6 (LTBI), 12 (LTBI + SIV co-infection, one week post cART + 3HP initiation), 16 (4 weeks post cART + 3HP initiation) and 22 (10 weeks post cART + 3HP initiation) (Fig. 1 K). The lung lesions in all RMs remained stable, i.e., no or minimal progression in size and architecture at week 6 after infection, confirming LTBI (Fig. 1 K). All three RMs that were scanned showed significant increase ( P = 0.01) 18F-fluorodeoxyglucose (18F-FDG) uptake in lung upon SIV co-infection and 1 week of cART + 3HP treatment at week 12 post Mtb infection indicating progression of TB pathology (Supplementary Fig. 1E). Scans at week 16 post Mtb infection (4 weeks of cART + 3HP treatment) showed decreased 18F-FDG uptake, though the decrease was not significant. We did not observe a further increase in volume of lung lesions (Supplementary Fig. 1D) or uptake of 18F-FDG (Supplementary Fig. 1E) at week 22 post Mtb infection (10 weeks of cART + 3HP treatment). PET/CT results therefore demonstrate a significant decrease in volume of lesions but not in their metabolic potential post cART + 3HP treatment, suggesting that concurrent treatment led to a progressively increased resolution of caseous lesions that had been formed post SIV co-infection (week 12) but did not reduce the ongoing inflammation in the few remaining lesions. Immune reconstitution by cART + 3HP in pulmonary compartment of Mtb/SIV co-infected RMs . Immunophenotyping of T cells was performed to assess both the extent and the quality of immune reconstitution by cART + 3HP relative to cART in pulmonary compartment of Mtb /SIV co-infected RMs. We have earlier demonstrated only partial restoration of depleted CD4 + T cells in BAL (Fig. 2 A) and lung (Fig. 2 B) after 12 weeks of cART in Mtb /SIV co-infected RMs, with significantly lower frequencies in lung tissue than those in the LTBI animals. 12 weeks of cART + 3HP treatment reconstituted CD4 + T cell frequency in BAL to comparable levels of LTBI (Fig. 2 A) but not in lung, where the CD4 + T cell frequency remained significantly lower than LTBI control (Fig. 2 B) ( P = 0.0021). A significantly increased percentage of CD8 + T cells was observed in BAL (Fig. 2 C) of cART + 3HP RMs compared to cART treated RMs ( P = 0.04 ) but not in lung (Fig. 2 D). The percentage of CD8 + T cells were not significantly different in lung of LTBI, cART and cART + 3HP treated, Mtb /SIV co-infected RMs. We have previously shown that chronic immune activation drives LTBI reactivation upon SIV co-infection in RMs [ 14 , 15 , 20 ]. To assess the impact of cART + 3HP on T cell activation, we studied expression of HLA-DR and CD69 on CD4 + T cells in BAL at week 11 post Mtb infection (or 2 weeks post SIV co-infection, prior to initiation of cART + 3HP) and at necropsy (end of 12 weeks of cART + 3HP treatment) in all 4 study groups. All Mtb /SIV co-infected groups exhibited increased frequencies of HLA-DR + - and CD69 + - CD4 + T cells at week 11 (peak viremia) compared to the LTBI group (Fig. 2 E, Fig. 2 F). cART + 3HP effectively reduced the percentage of CD4 + T cells expressing HLA-DR and CD69 compared to cART naïve RMs, but not to the levels seen in LTBI or cART treated RMs. The increased activation of CD4 + T cells may be attributed to tuberculosis-immune reconstitution inflammatory syndrome (TB-IRIS) with concurrent cART + 3HP. High expression of PD-1 marker on T cells is often associated with increased exhaustion and T cell dysfunction in chronic infections such as HIV despite cART [ 21 , 22 ]. To study the impact of cART + 3HP on T cell exhaustion in Mtb /SIV co-infection, we determined the percentage T cells expressing PD-1 in BAL cells at week 11 (peak viremia) and necropsy (Fig. 2 G). cART and cART + 3HP treated RMs demonstrated significantly higher percentage of PD-1 + CD4 + T cells compared to LTBI RMs at necropsy. Addition of 3HP to cART did not alleviate T cell exhaustion in pulmonary compartment as seen by no significant difference in PD-1 expressing CD4 + T cells in BAL between cART and cART + 3HP treated RMs (Fig. 2 G). This was in spite the fact that virtually no detectable Mtb and SIV were present at the end of the protocol in the concurrently treated RMs. Overall, we conclude that cART + 3HP fails to control immune activation post SIV co-infection of LTBI leading to exhaustion of CD4 + T cells in pulmonary compartment. We hypothesize that the duration and magnitude of immune activation dictates the incapability of T cells to elaborate the usual array of functional effector responses in Mtb /SIV co-infection. It is important to note that increased turnover is not observed in the macrophages (Figs. 2 K and 2 L). A significantly lower ( P < 0.05) percentage of macrophage turnover was observed in the lungs of RMs treated with cART + 3HP compared to cART and cART naïve RMs (Fig. 2 L). A higher number of BrDU + nuclei (green) within macrophages (red) as indicated by white arrows was seen in lung of cART naïve and cART treated RMs but was absent in lung of cART + 3HP treated RMs (Fig. 2 K). We further studied the impact of cART + 3HP on T H17 and T H1* phenotypes in the pulmonary compartment of Mtb /SIV co-infected RMs. A significantly higher percentage of CD4 + T cells expressing CCR6, a regulator of migration and function of T H17 cells was observed in BAL cells of cART and cART + 3HP treated RMs (Fig. 2 H) compared to LTBI and cART naïve RMs at necropsy. Similarly, we observed a significantly higher percentage of CD4 + T cells co-expressing CXCR3 and CCR6 in cART and cART + 3HP treated RMs compared to LTBI and cART naïve RMs, in both, BAL and peripheral blood cells (Figs. 2 I and 2 J). Additionally, cART + 3HP treated RMs harbored a significantly higher percentage of CXCR3 + CCR6 + CD4 + T cells (T H1* ) in local and peripheral compartments compared to cART treated RMs (Figs. 2 I and 2 J). These findings align with our previous observation that higher frequencies of CD4 + T cells co-expressing CXCR3 and CCR6 associate with bacterial control in Mtb /SIV co-infection [ 23 ]. It has been previously reported that T H1* subset is the most frequent Mtb -specific T cell subset in the lungs of latent TB donors and that their numbers are increased when compared to healthy subjects [ 24 ]. The higher percentage of CXCR3 + CCR6 + CD4 + T cells in local and peripheral compartments could also be attributed to cART mediated control of viral replication as CXCR3 + CCR6 + cells are known to be preferential targets of HIV/SIV infection [ 24 , 25 ]. Further, a reduction in this cell subset could be attributed to higher rates of LTBI reactivation. Thus, treatment of Mtb /SIV co-infected RMs with cART + 3HP increases migration of T H17 and T H1* cells into pulmonary compartment compared to cART naïve RMs. Poor recovery of effector memory T cells by cART + 3HP in Mtb/SIV co-infected RMs. To investigate functional immune reconstitution by cART + 3HP in pulmonary compartment of Mtb /SIV co-infected RMs, we further immunophenotyped the partially replenished CD4 + T cells into central memory (CD28 + /CD95 + ) (CD4 + T CM ) and effector memory (CD28 − /CD95 + ) T cells (CD4 + T EM ) (Supplementary Fig. 2). SIV co-infection of latent Mtb infection caused a significant increase in percentage of CD4 + T CM in BAL at week 11 (peak viremia prior to cART + 3HP treatment) ( P < 0.0001 ) (Fig. 3 A; Supplementary Fig. 3A). The increased percentage of CD4 + T CM persisted during and till end of the 12 week-long concurrent cART + 3HP treatment. On the contrary, a significant decline occurred in the frequency of CD4 + T EM in BAL at peak viremia which marginally increased at end of 12 weeks cART + 3HP treatment (Fig. 3 B; Supplementary Fig. 3A). However, the percentage of CD4 + T EM at necropsy was significantly lesser than that seen in LTBI phase of the study (week 3 post Mtb -infection) ( P = 0.002 ). These findings align with our previous observation that cART treatment fails to replenish the depleted CD4 + T EM in BAL and lung of Mtb /SIV co-infected RMs [ 15 ]. Immunophenotyping of BAL CD8 + T cells into CD8 + T CM and CD8 + T EM showed a significant increase ( P = 0.01 ) in percentage of CD4 + T CM at peak viremia (week 11 post- Mtb infection or 2 weeks post SIV co-infection). This increase was mitigated by cART + 3HP as seen by marginally reduced percentage at necropsy ( P = 0.01 ) (Fig. 3 C; Supplementary Fig. 3B). No significant change was observed in percentage of CD8 + T EM in BAL at weeks 3, 11 and 24 (Fig. 3 D; Supplementary Fig. 3B) ( P = 0.2 ). Thus, cART + 3HP expands the CD4 + and CD8 + T CM but is unable to replenish the CD4 + T EM in pulmonary compartment of Mtb /SIV co-infected RMs. We further compared the restoration of CD4 + T CM and CD4 + T EM in BAL and lung of Mtb /SIV co-infected RMs treated with cART or cART + 3HP (Figs. 3 E- 3 L). Despite similar percentage of CD4 + T cells in BAL at necropsy, there was a significantly higher percentage ( P < 0.0001 ) of CD4 + T CM in cART + 3HP treated RMs compared to cART treated RMs (Fig. 3 E). No significant difference was observed in lung CD4 + T CM (Fig. 3 F), BAL CD4 + T EM (Fig. 3 G) and lung CD4 + T EM (Fig. 3 H) between cART and cART + 3HP treated RMs. Similar to CD4 + T CM , cART + 3HP RMs exhibited significantly higher ( P = 0.009 ) percentage of CD8 + T CM in BAL (Fig. 3 I) with a concurrent decrease in CD8 + T EM (P < 0.0001) (Fig. 3 K) compared to cART treated RMs. However, there was no significant difference between lung CD8 + T CM (Fig. 3 J) and CD8 + T EM (Fig. 3 L) in cART and cART + 3HP treated RMs. Overall, there were dynamic changes in the memory phenotype of CD4 + and CD8 + T cells in BAL compared to lung in cART and cART + 3HP treated RMs. BAL is a critical resource to study longitudinal changes in pulmonary immune response and has been shown to be useful to evaluate local response to therapy [ 26 , 27 ]. cART + 3HP increases Mtb-specific T H1 /T H17 response in pulmonary compartment of Mtb/SIV co-infected RMs. BAL samples were collected from study RMs at weeks 5, 11 and necropsy post Mtb infection using standard operating procedures by the veterinarian. Single cell suspensions were prepared as per the lab standardized protocol [ 28 ]. All Mtb -specific responses were background corrected (Supplementary Fig. 5). BAL cells were stimulated ex vivo with Mtb -specific antigens, ESAT-6/CFP-10 and Mtb Cell Wall Fraction ( Mtb CW) for 16 h and stained with flow cytometry antibodies to detect IFNg, TNFa, and IL-17. A significantly higher percentage of IFNg expressing Mtb -specific CD4 + T cells was seen in BAL of cART + 3HP treated RMs at end of treatment when stimulated with ESAT-6/CFP-10 (Fig. 4 A) ( P = 0.04 ) and Mtb CW (Fig. 4 B) ( P = 0.009 ) compared to cART treated RMs. We hypothesize that cART + 3HP treatment effectively control bacteria thus enhancing production of protective IFNg by Mtb -specific CD4 + T cells in pulmonary compartment of Mtb /SIV co-infected RMs [ 29 ]. In contrast to IFNg, cART + 3HP treatment resulted in a significantly lower percentage of Mtb -specific CD4 + T cells to produce TNFa in response to stimulation with either ESAT-6/CFP-10 (Fig. 4 C) ( P = 0.03 ) or Mtb CW (Fig. 4 D) ( P = 0.009 ) compared to cART treated RMs. It has been reported previously that T-cell derived TNFa is essential for sustained protection during chronic Mtb infection [ 30 ] and that TNFa can promote proliferation of effector T cells resulting in increased immunogenicity [ 31 , 32 ]. It has been demonstrated that antigen-specific expression of TNFa in the absence of IFNg on CD4 + T cells in Mtb -infected patients strongly correlates with the potential to develop active TB, while the opposite phenotype is supportive of latent infection [ 33 , 34 ]. Our results therefore suggest that concurrent cART + 3HP treatment results in the clearance of bacterial infection. Thus, concurrent treatment with cART + 3HP does not result in increased production of Mtb -specific TNFa which in turn has a detrimental impact on effector function needed for sustained protection. Similar to IFNg, a significant increase in IL-17 + CD4 + T cells was observed in BAL of cART + 3HP treated RMs when stimulated with ESAT-6/CFP-10 (Fig. 4 E) ( P = 0.01 ) and Mtb CW (Fig. 4 F) ( P = 0.005 ) compared to cART treated RMs. The trends were similar in lung with significantly higher percentage of CD4 + T cells expressing IFNg ( P = 0.04 ) and IL-17 ( P = 0.01 ) when stimulated with ESAT-6/CFP-10 (Fig. 4 G) or Mtb CW (Fig. 4 H) compared to cART treated RMs. While the role of T H1 cells is clearly associated with protection in Mtb infection through IFNg production, the role of T H17 cells is complex and is associated with tissue damage on one hand and anti-inflammatory response on the other hand. However, our findings align with the recent studies that show that Mtb -responsive IL-17- producing CD4 + T cells are preserved in humans with LTBI with HIV-ART and that IL-17 producing CD4 + T cells constitute the dominant response to Mtb antigen [ 35 ]. Moreover, we did not observe an increase in levels of pro-inflammatory cytokines, IL-6 and IP-10 in cART + 3HP treated RMs compared to cART treated RMs (Fig. 4 I). Overall, there is an increased T H1 /T H17 Mtb -specific response in cART + 3HP treated RMs that associates with protection but also has the potential to be pathological. In contrast we observed a decreased Mtb -specific TNFa response after concurrent treatment that could have detrimental impact on long term protection. To better understand immune responses after concurrent cART + 3HP treatment relative to cART-treatment, we assessed transcriptional profiles of lung cells collected at necropsy from Mtb /SIV co-infected, cART or cART + 3HP treated RMs by RNA sequencing (Fig. 4 J). Mtb is known to manipulate cell death pathways to evade host immunity, thereby protecting the bacilli from antibiotics, and allowing dissemination when timing is appropriate [ 36 ].Gene terms associated with cell death, apoptosis, death receptor signaling, and necrosis were highly enriched amongst induced genes from the lungs of cART + 3HP treated, compared to cART treated RMs (Fig. 4 J). The increased expression of apoptosis-related genes could also be attributed to presence of antibiotics (isoniazid and rifapentine) that are known to cause oxidative damage in host cells, leading to increased apoptosis in addition to Mtb control [ 37 ]. An increased expression of Type I IFN genes, such as IFNA2, IFNA1/IFNA13 was seen in cART + 3HP treated RMs compared to cART treated RMs (Fig. 4 J). The role of Type I IFN in TB is ambiguous. Both human and animal studies show evidence for the role of Type I IFN in Mtb expansion and disease pathogenesis [ 38 ]. Murine data particularly suggests that Type I IFN signaling promotes TB progression. Our own data from RMs suggests that pDC expressing Type I IFN associate with TB progression [ 39 , 40 ]. A human blood transcriptional signature also largely comprised of Type I IFN response genes was described in TB patients [ 41 ] and validated in macaques with TB [ 42 ]. We have previously shown the enrichment of the Type I IFN signatures among the lymphoid cell clusters from the lungs of Mtb -infected mice [ 43 ]. Together, these results suggest a pathological role for Type I IFN in TB. Thus, our finding of an increased Type I IFN signature aligns with previously reported transcriptional signatures in human and NHP experiments [ 41 , 44 ] and suggests that while clinical disease is controlled by concurrent therapy, these animals continue to harbor molecular signatures associated with TB pathology and immune activation in the lung. Single cell transcriptomic signature in pulmonary compartment of Mtb/SIV co-infected RMs . We further investigated the transcriptional changes at single cell level in the pulmonary compartment of Mtb /SIV co-infected RMs treated with cART + 3HP. We collected BAL at four critical time points from the same RMs during the study period; week 5 (represents the asymptomatic phase of Mtb infection), week 11 (represents 2 weeks post-SIV co-infection), week 13 (represents post-SIV co-infection and 4 weeks of cART treatment) and necropsy (study endpoint after 12 weeks of cART + 3HP treatment) (Fig. 5 A; Supplementary Fig. 6A, 6B). Using this experimental design, we were able to track the early transcriptomic changes in defined populations of cells at four different stages of Mtb /SIV co-infection. This negates the need for LTBI- and cART-naïve controls since they are represented by week 5 and week 11 timepoints in this study. All samples passed quality control in terms of cell quality (fraction reads in cells) and sequencing after which they were run on 10x chromium controller (Supplementary Table 1; Fig. 5 B and 5 C). Uniformed Manifold Approximation and Projection (UMAP) clustering identified 14 transcriptionally distinct cell clusters across all samples that can be broadly classified into lymphoid, myeloid and non-lymphoid, non-myeloid (Fig. 5 D, Supplementary Fig. 7A, 7B). Lymphoid clusters include C3 (CD4 + memory T cells; ADAM23 + , CAMK4 + , CD96 + , CLEC2D + , ITK + ), C6 (CD8 T cells; CCR5 + , CD3D + , CD3E + , CD8A + , CD8B + , ITM2A + , C10 (NK cells; NCAM1 + , EOMES + , GNLY + , GZMA+, KLRB1 + , HOPX + ), C11 (B cells; AFF3 + , AKAP2 + , BLK + , CD19 + , CD79A + , CNR2 + , CR2 + , EBF1 + ); Myeloid clusters include C0 (M2 macrophages; MRC1 + , ALDH2 + , APOE + , ARL11 + , CD63 + , CD14 + , GSTO1 + , RAB13 + , DNASE2B + ), C1 (M1 macrophages; IL-6+, IL-8+, SLC11A1 + ), C4 (Monocytes; CD14 + , CD163 + , CD68 + ), C5 (Neutrophils; ABHD2 + , ANO2 + , CACNA1D + , CACNB4 + , HAL + , MCTP1 + , MITF + , TCF7L2 + ), C7 (mDC; CD1A + , CLIC2 + , DSE + , FLT3 + , EMP1 + , P2RY6 + ), C9 (Granulocytes; FCGR3 + , FPR1 + , MNDA + , CSF3R + ), C12 (Basophils; CD63 + , ENPP3 + ), and C13 (Mast cells; CD117 + , CD203c + , CD63 + ). Non lymphoid non myeloid clusters include C2 (Ciliated cells; STK11 + , MARK3 + ), C8 (Endothelial cells; FOXJ1 + , DNAH5 + , TEKT1 + ) and C14 (mesenchymal stromal cells; CD44 + , CD79A + ). The total number of transcripts (nFeature_RNA) and molecules (nCount_RNA) detected within each cell increased in early phase of SIV co-infection compared to LTBI phase (Figs. 5 E and 5 F). Cells were filtered to detect genes within the range of 10-8000 to remove extremely low and high counts. The plot shows the distribution of detected gene levels of cells, and the colored shapes represent the distribution density (Figs. 5 E and 5 F). The nFeature_RNA and nCount_RNA remained at higher levels at the end of cART + 3HP treatment (necropsy time point) compared to LTBI phase of study (wk 5 time point). Based on published signature gene list, we analyzed T H1 ( TBX21, IFNG, TNF, LTA, IL18RAP, BHLHE40, STAT1 ), T H2 ( IL-4, IL-5, IL-6, IL-10, IL-13, KLF4, TCR ) and T H17 ( CCR6, RORA, RORC, IRF4, STAT3, IL23R, IL22 ) associated transcriptional changes in lymphoid (Fig. 6 A) and myeloid (Fig. 6 B) clusters at the pre-determined time points in BAL of Mtb /SIV co-infected, cART + 3HP treated RMs (Supplementary Fig. 8). Relative to the LTBI phase time point (wk 5), an increased expression of genes BHLHE40, STAT1, RORA, STAT3, KLF6 was observed in lymphoid clusters and myeloid clusters at end of treatment with cART + 3HP (Fig. 6 A, 6 B and Supplementary Fig. 9). IL23R was expressed at higher levels at all time points in CD4 + memory T cell and CD8 + T cell clusters. CD8 + T cell cluster showed increased expression of activation marker genes; KLRD1, CCL5, GZMB, GZMH, CTLA4, ICOS, LAG3 . However, it is to be noted that not all T H1 and T H17 associated genes were up regulated in lymphoid and myeloid clusters post cART + 3HP treatment. We did not observe an increased expression of IL2 , TBX21, IFNG, TNF, LTA, IL18RAP, IL22, RORC, IRF4, CCR6 at necropsy (end of cART + 3HP) compared to wk 5 post Mtb infection (LTBI phase) (Fig. 6 A, 6 B and Supplementary Fig. 9). Negligible expression of T H2 -associated genes was observed at all time points in both lymphoid and myeloid clusters (Fig. 6 A, 6 B and Supplementary Fig. 9) except for high expression of KLF4 in myeloid clusters. Additionally, there was a high expression of LAG3, an exhaustion marker, and CD38, an immune activation marker in CD8 + T cell cluster post SIV co-infection at wk 11 and at end of cART + 3HP treatment at necropsy. Overall, we hypothesize that cART + 3HP mediates the increased T H1 /T H17 response in pulmonary compartment through increased expression of BHLHE40, STAT1, RORA and STAT3 . Discussion We report here for the first time the impact of WHO-recommended cART + 3HP treatment regimen on LTBI reactivation in Mtb /SIV co-infected rhesus macaques in the presence of cART. As such, our results provide unprecedented, novel insights into the host response to co-infection and concurrent treatment. 3HP combines high dose isoniazid and rifapentine and is a once weekly, 12-week therapy taken orally. In humans, 3HP is associated with significantly lower hepatotoxicity and higher rates of completion than isoniazid preventive treatment [ 45 , 46 ]. It is important to note that 3HP is a recommended regimen to treat LTBI and prevent TB in persons living with HIV. Recent clinical trials (Dolphin-study) have shown that for people starting anti-HIV treatment, combining dolutegravir containing cART with 3HP TB preventive treatment is safe and works efficiently in tandem [ 47 ] with high rates of viral suppression. Modeling concurrent cART + 3HP in Mtb /HIV co-infection using a relevant animal model, such as NHPs, provides an invaluable tool to investigate the impact on local immune responses. The NHP model is attractive for studying human Mtb infection and for performing preclinical studies on treatment regimens as it recapitulates key aspects of human Mtb infection states and TB disease [ 48 – 51 ]. Our group has previously shown that earlier initiation of cART suppresses the virus, partially reconstitutes CD4 + T cells but fails to control inflammation and immune activation [ 15 , 20 ]. We have also shown that administration of 3HP failed to sterilize bacteria in the lung of latently infected RMs with 2 of the 6 RMs showing culturable Mtb in the lungs (~ 3 logs), 4 to 5 weeks post-SIV co-infection [ 13 ]. In this study, we sought to determine if concurrent cART + 3HP therapy initiated at early stages of co-infection better controls immune dysfunction in pulmonary compartment compared to cART. Administration of concurrent cART + 3HP improved the clinical and microbiological attributes of Mtb /SIV co-infection compared to cART naïve or cART treated RMs. RMs were trained to take 3HP orally mimicking humans. As seen in the DOLPHIN study, our model demonstrated that co-administration of dolutegravir with 3HP was safe, well-tolerated and did not require any dose-adjustment of dolutegravir. Initiation of cART and 3HP at 2 weeks post Mtb /SIV co-infection sterilized bacterial burden in lung of 5 out of 6 RMs and completely prevented dissemination to extra-pulmonary organs in all 6 RMs. There was a significant reduction in percent lung involvement in pathology in cART + 3HP treated RMs with visibly fewer granulomas compared to cART naïve or cART-treated RMs. The few granulomas observed at end of cART + 3HP treatment were characterized as an equal mix of non-necrotizing and caseous type. 18F-FDG PET/CT scans revealed a significant reduction in number of lesions post treatment with cART + 3HP but not in uptake of 18F-FDG in the few lesions that remained at ned of treatment. Taken together, cART + 3HP treatment exerts bacterial and viral control, thereby improving the health status of Mtb /SIV co-infected RMs during the study period. However, cART + 3HP treated RMs continued to harbor granulomas that have the potential to release infectious bacilli and exhibit increased 18F-FDG uptake associated with inflammation. We next investigated immune reconstitution in the pulmonary compartment of RMs treated with cART + 3HP compared to LTBI, cART naïve and cART-treated RMs. We have previously shown that cART is unable to reconstitute CD4 + T cells in the lung tissue to the levels seen in LTBI and that the reconstituted CD4 + T cells are dysfunctional for Mtb -specific response [ 15 , 20 ]. Concurrent administration of cART and 3HP did not further improve the frequency of reconstituted CD4 + T cells in lung of Mtb /SIV co-infected RMs compared to cART only treated RMs. The reconstituted CD4 + T cells in BAL and lung of cART + 3HP treated RMs exhibited an increased frequency of activated and inflamed phenotype compared to LTBI RMs. Activated CD4 + T cell phenotype associates with high risk for TB progression. Our model therefore demonstrates that SIV-induced activation of pulmonary CD4 + T cells is not ameliorated by cART + 3HP. A majority of reconstituted CD4 + T cells appeared to be central memory phenotype. On the contrary, there was a significant reduction in the effector memory CD4 + T cells population in pulmonary compartment post SIV co-infection that cART + 3HP did not alleviate as was also seen in cART treated RMs. CD4 + T EM cells are critical for host protection to subsequent antigen encounter. The effector memory CD4 + T cells can produce early effector cytokines such as IFNg and TNFa that help activate other cell types such as CD8 + T cells or they can directly kill the infected cells. It is feasible that reduced bacterial burden results in reduced antigen presentation which can cause a reduced frequency of CD4 + T EM cell in cART + 3HP treated RMs. However, chronic Mtb infection such as a latent TB infection is known to elicit effector memory phenotype in CD4 + and CD8 + T cells [ 52 ]. Our model recapitulates this phenotype as is seen by > 10% CD4 + T EM in BAL collected from the same RM during LTBI phase that reduces to less than 3% post SIV co-infection. Clearly, the presence of CD4 + T EM associates with an immune balance seen in LTBI in our model and a decrease in the frequency of this cell type contributes to immune dysfunction that cART + 3HP fails to mitigate. We next determined the percentage and functionality of Mtb -specific CD4 + T cells in pulmonary compartment of Mtb /SIV co-infected RMs treated with cART + 3HP compared to cART. We performed ex vivo stimulation of BAL cells isolated at week 5 (represents the asymptomatic phase of Mtb infection), week 11 (represents 2 weeks post-SIV co-infection), and necropsy (after 12 weeks of cART + 3HP treatment) with ESAT-6/CFP-10 and Mtb CW. Upon 12 weeks of cART + 3HP treatment, an increased percentage of IFNg and IL-17 producing Mtb -specific CD4 + T cells was seen in BAL and lung. Similar to what has been reported in humans, it is feasible that a majority of these T H1 /T H17 cytokine producing cells in BAL and lung are of central memory phenotype since CD4 + T CM were the dominant cell type observed in pulmonary compartment at end of cART + 3HP treatment [ 53 ]. On the contrary, a lesser percentage of TNFa- producing Mtb -specific CD4 + T cells was observed at the end of cART + 3HP treatment compared to cART treated RMs. TNFa is required for granuloma organization and inhibition of TNFa through TNFa inhibitors result in TB reactivation [ 54 ]. Hence, the skewed reconstitution of Mtb -specific response consisting of an increased IFNg and IL-17 response but a defective TNFa response could prove detrimental in long-term protection, altered granuloma formation and dissemination of disease. Bulk RNA sequencing of lung tissue collected at necropsy from cART + 3HP treated RMs showed increased type I IFN response-associated genes; “ Interferon signaling ”, “ IFNA2 ”, “ IFNA1/IFNA13 ”, “ ifnar ”, “ interferon alpha ”, “ IRF9 ”, “ IRF1 ” and apoptosis genes; “ Apoptosis ”, “ Apoptosis of epithelial cells ”, “ cell death of progenitor cells ”, “ cell death of germ cells ”, “ Apoptosis of hematopoietic cells ” compared to cART treated RMs. Type I IFN are critical in host defense to viruses. However, there is a growing body of literature that describes the detrimental impact of type I IFN in Mtb infection [ 55 , 56 ]. In humans, type I IFN is associated with loss of control and progression to TB disease [ 57 , 58 ]. Recently, type I IFN was shown to play a role in Mtb -induced macrophage cell death that leads to release of bacilli from dead macrophages and dissemination. Previously, it was shown that the signaling pathways involved with type I IFN are involved in apoptosis [ 59 , 60 ] that explains the concomitant increase in expression of genes associated with apoptosis in cART + 3HP treated RMs. Overall, RMs treated with cART + 3HP present a distinct transcriptomic signature that associates with immune cell death. A deeper analysis of immunological recovery at the single cell level confirmed increased expression of genes associated with immune control of Mtb including, CD4 + memory T cells, CD8 + T, NK cells, B cells, M1/M2 macrophages, granulocytes and epithelial cells. Concurrent with the flow cytometry data, scRNAseq showed an increased expression of certain T H1 and T H17 -associated genes in lymphoid clusters at end of cART + 3HP treatment. CD8 + T cell cluster was characterized by an activated signature with substantially higher cytotoxic function-associated gene expression compared to CD4 + memory T cells, NK and B cells. One possibility could be that this increased cytotoxic gene signature in CD8 + T cell cluster associates with the increased apoptotic signature seen in bulk RNAseq since release of cytotoxic molecules by CD8 + T cells is known to cause apoptosis of target cells [ 61 ]. In humans on cART, increased expression of immune activation marker, CD38 on CD8 + T cells during chronic HIV infection associates with the inability to proliferate and increased exhaustion. Overall, it is important to note that while cART + 3HP effectively controls the virus and the bacilli, there is disproportionate reconstitution of memory subsets, levels of activation and exhaustion markers as well as their functional capacity. There are some limitations to this study. Since functional restoration of CD4 + and CD8 + T cells is a gradual process in humans, our study, with a window of ~ 3 months post-treatment, may not recapitulate these settings exactly. We necropsied the RMs at the end of 12-week cART + 3HP treatment to match time points with previous cohorts. To study long-term immune reconstitution by cART + 3HP, we are now planning future studies with extended time to necropsy post treatment completion. Another caveat is that the model may not provide a full physiological recapitulation of human Mtb /HIV co-infection, because RMs are exposed to a supraphysiological dose of SIV. Not all humans on cART are likely to exhibit treatment failure and progression to TB reactivation. However, Mtb /HIV co-infected individuals on cART remain ~ 10- fold more likely to reactivate than HIV-naïve people with LTBI [ 62 , 63 ]. Humans likely develop LTBI with a substantially lower infectious dose of Mtb (1–2 CFU) than we use to infect RMs (~ 10–15 CFU Mtb CDC1551). RMs infected with the CDC1551 dose/strain combination exhibit control of Mtb infection akin to human LTBI, yet the dose is higher than the physiologically relevant human infectious dose. Hence, our results are indicative of the worst outcomes in co-infected humans. We infect the RMs through aerosol, the natural route of infection, mimicking humans. Mtb strain, CDC1551 allows for the development of a human TB model resulting in a latent to chronic rather than active TB disease [ 48 ]. CDC1551 has also been shown to induce a protective immune response despite being similar in virulence to other lab strains [ 64 ]. Thus, our model allows for an in-depth analysis of the clinical and immunological response in the lung to cART + 3HP, which is possible only in a handful of research institutions world-wide. We are currently however, engaged in performing experiments with samples from human cohorts to validate our results. In conclusion, while concurrent cART and 3HP effectively suppress the virus and bacteria, the quality of immune reconstitution in the pulmonary compartment remains significantly sub-optimal. cART + 3HP treatment increases the T H1 /T H17 response in lung but there is incomplete restoration of protective, CD4 + T EM and replenished Mtb -specific CD4 + T cells are skewed in their ability to produce TNFa. Though concurrent therapy improves pathological burden, there is increased 18F-FDG uptake in the few lesions that remain despite treatment. Further, transcript analysis of lung and BAL showed an increased expression of CD38, an immune activation marker on CD8 + T cells, as well as of apoptotic signature characteristic of cell death. Our results clearly show that despite the mitigation of co-infection, chronic immune activation persists in the lungs of concurrently treated NHPs. Targeting the host immune response via a host-directed immunotherapy provides an opportunity to augment immunity during the short-window of acute HIV-1 co-infection of Mtb. Future studies should perform testing of safety and efficacy of novel host-directed therapies such as IL-21-IgFc fusion protein administration or use of IDO-1 inhibitors concurrent to standardized therapies in tissues and organs like the lung, that are impossible to access in humans. This is critical for the development of an immune-based intervention along with cART and anti-TB therapy to control dysregulated immune responses generated during early events of HIV co-infection of LTBI and provide long-term immune reconstitution. Methods Animal infection . This study included macaque data from completed studies [ 15 , 19 , 65 ]. A total of 18 specific pathogen free Indian-origin rhesus macaques ( Macaca mulatta ) were infected with a low dose of approximately 10 CFU M. tuberculosis CDC1551 (BEI Resources, catalog NR13649) via aerosol as described before [ 28 , 66 – 68 ] (Supplementary Table 2). TST was performed at weeks 3 and 5 post TB infection to confirm infection. All the RMs were monitored for CRP, percent body weight and body temperature weekly through the study period. 14 of the LTBI RMs were then co-infected with 300 TCID 50 SIVmac 239 via the intravenous route 9 weeks post-TB infection [ 15 , 17 , 19 , 65 ] (provided by the Preston Marx Laboratory, TNPRC, Covington, Louisiana, USA). All the procedures were conducted a board-certified veterinary clinician. The remaining 4 RMs served as LTBI controls for the study. The viral infection was confirmed through plasma viral loads via reverse transcription quantitative PCR (RT-qPCR). Upon confirmation of SIV infection, the 18 RMs were then divided into 3 groups: the first group of 8 RMs served as co-infected controls with no cART administration; the second group of 4 RMs were started on cART at 2 weeks post-SIV co-infection or 11 weeks post TB infection (cART at peak viremia) and the third group of 6 RMs started cART + 3HP at 2 weeks post-SIV co-infection once weekly for 12 weeks. All the RMs in cART-naive group had to be euthanized within 2–4 weeks of cART treatment due to clinical signs of TB reactivation. The RMs in the cART group were euthanized after 9 weeks of cART treatment while the RMs in cART + 3HP group were euthanized at end of 12-week treatment at week 24. cART + 3HP regimen. Co-infected RMs received a drug regimen consisting of 20 mg/kg of (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA, tenofovir, Gilead Sciences), 30 mg/kg of 2’, 3’-dideoxy-5-fluoro-3’-thiacytidine (FTC, emtricitabine, Gilead Sciences) and 2.5 mg/mL of the integrase inhibitor, DTG, Dolutegravir (ViiV Healthcare). The drugs were administered daily via subcutaneous injection of a cocktail of these three drugs in the vehicle kleptose at previously published doses [ 19 ]. Co-infected RMs also received a weekly oral dose of 15mg/kg isoniazid and 15 mg/kg rifapentine for 12 weeks beginning week 12 after aerosol infection up to week 23 post-TB infection. Oral intake was monitored by veterinary staff to ensure consumption. Positron emission tomography-computed tomography (PET/CT) imaging. Longitudinal CT and PET/CT scans were performed using MEDISO’s LFER150 PET-CT scanner at 3–6 week intervals, starting from week 6 post- Mtb infection with the last scan prior to necropsy [ 69 ]. Briefly, we performed 18F-fluorodeoxyglucose (FDG) PET/CT scans for each anesthetized RM using the breath-hold technique. RMs were anesthetized and intubated under supervision of a board-certified veterinarian as per approved IACUC protocols. All the RMs received an intravenous injection of 1 mCi per kg of body weight dose of 18F-FDG [ 70 ], procured from Cardinal Health radiopharmacy. The single field of view (FOV) and/or double FOV lung CT scans were performed using breath-hold as described [ 71 ]. PET scans were acquired after completion of the 40–50 min FDG uptake period. Images were visualized using Interview Fusion 3.03 (Mediso) and reconstructed using Nucline NanoScan LFER 1.07 (Mediso) with parameters as described [ 72 ]. The lung segmentation, volumetric and SUV analysis was performed using Vivoquant 4.0 (Invicro, USA) [ 69 ]. Viral load and bacterial burden measurement . Bacterial burden in BAL was measured throughout the study period as previously described [ 17 ]. Viable Mtb burden was also measured at necropsy in BAL, lung, spleen, bronchial lymph node and individual granulomas collected at necropsy [ 17 , 65 ]. Viral loads in acellular BAL supernatant and plasma were determined by RT-qPCR at peak viremia (2 weeks post-SIV or 11 weeks post TB-infection), week 13, week 15 post- Mtb infection and at necropsy. The measurements were performed by NIAID, DAIDS, Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development). A lower limit of 100 copies/ sample was set for quantification of SIV copies in this assay. High parameter flow cytometry . High parameter flow cytometry was performed on BAL cells at pre-infection, pre-SIV (wk 3, 5), post-SIV, pre-cART (wk 11), post-cART (wk 20 or necropsy) and post-cART + 3HP (wk 24 or necropsy). Lung, bronchial lymph nodes and granulomas were harvested at necropsy and processed as described earlier [ 15 , 17 , 65 ]. The single cells prepared were then stained with surface and intracellular markers to study various cell phenotypes (Supplementary Table 3). The freshly collected BAL cells were stimulated ex vivo with Mtb -specific antigens, ESAT-6/CFP-10 and Mtb Cell Wall Fraction (BEI Resources, 10 µg/mL) for a total of 16 h. Brefeldin A (0.5 µg/mL, SIGMA) was added 2 h after the onset of stimulation. After stimulation, the cells were stained with LIVE/DEAD fixable Near-IR stain (ThermoFisher) and stained subsequently with the surface antibodies: CD4-PerCP-Cy5.5 (BD Biosciences), CD8-APC (BD Biosciences), CD3-AlexaFlour 700 (BD Biosciences), CD95-BV421 (BD Biosciences), CD28-PECy7 (BD Biosciences) and CD45-BUV395 (BD Biosciences). Cells were then fixed, permeabilized and stained with intracellular antibodies: IFNγ - APC-Cy7 (Biolegend), IL-17-BV605 (Biolegend) and TNFα - BV650 (Biolegend). Cells were washed, suspended in BD stabilizing fixative buffer and acquired on BD FACS Symphony flow cytometer. Analysis was performed using FlowJo (v10.6.1) using previously published gating strategy [ 15 , 17 , 19 , 68 ]. Gross pathology . The animals were euthanized for necropsy and lung lobes, spleen, liver, bronchial lymph nodes were collected. All the tissues were weighed at the time of collection. Tissues were fixed in 10% neutral-buffered formalin, paraffin embedded, sectioned at 5 µm thickness and stained with hematoxylin and eosin using standard methods. Lung tissues were collected stereologically at necropsy and stereology scores were prepared on percentage lung affected by a board-certified veterinary pathologist. Immunohistochemistry staining . Fluorescent immunohistochemistry was performed on formalin-fixed, paraffin-embedded lung and bronchial lymph node tissues as previously described [ 15 , 16 , 19 , 65 , 73 ]. The stained slides were scanned in the Axio Scan Z1 and the images were analyzed using HALO software. Study Approval All infected animals were housed under Animal Biosafety Level 3 facilities at the Southwest National Primate Research Center, where they were treated according to the standards recommended by AAALAC International and the NIH guide for the Care and Use of Laboratory Animals. The study procedures were approved by the Animal Care and Use Committee of the Texas Biomedical Research Institute. Quality control for frozen BAL cells . Prior to running the BAL cells on 10x Genomics platform, the cells were analyzed for viability using i) automated cell countess, ii) manual counts using Trypan Blue and iii) microscopic evaluation. Briefly, cells were thawed on ice. 100 µL of cells was washed once in 1 mL warmed 1x phosphate buffered saline (PBS) (Gibco), centrifuged, and resuspended in 1 mL of 1x PBS. Cells were mixed in 1:1 ratio with Trypan blue and counted in automated countess as well by hemocytometer (Supplementary Table 1). Cellular morphology, including shape and size was determined using a standard bright field light microscope. Institutional approved protocols were applied when removing samples from BSL3. Single cell RNA Library generation and sequencing . BAL cell suspensions were loaded onto Chromium instrument (10x Genomics) to generate single-cell beads in emulsion. Single-cell RNA-seq libraries were then prepared using Single Cell 3’ Gel bead and library kit version 3.1 (10× Genomics). Single cell barcoded cDNA libraries were quantified and sequenced on an Illumina NovaSeq 6000. Read lengths were 28bd for read 1, 10bp for index 1, 10bp for index 2, and 100bp for read 2. Cells were sequenced to about 50,000 reads per cell. Single cell data analysis . Cell ranger Single Cell Software suite (V7.0.1) from 10x was used to perform sample demultiplexing and generate fastq files. Resulting fastq files were aligned against reference genome mmul10 (Genebank, https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_003339765.1/ ) with cellranger count. The targeted cell recovery per sample was set to 10,000 cells. The cellranger counting results for 16 samples were further integrated and analyzed by R software with package Seurat (V4.4.0). The data matrix for each sample was read by Read10X and filtered by removing cells which have more than 8000 detected genes in each sample. All 16 samples data were merged, normalized with method “LogNormalize”, and most variable genes were detected by the FindVariableFeatures function with nfeatures 2000. Anchor genes were selected by SelectIntegrationFeatures and FindIntegrationAnchors, and further applied to integrated dataset by IntegrateData. The integrated data were scaled by ScaleData and principal component analysis [ 74 ] was performed by RunPCA with npcs = 30. To visualize the data, the TSNE dimensionality reduction was performed using the first 20 PCA. Data clustering was run by FindNeighbors (pca 20) and FindClusters (resolution 0.2). Basic marker genes for each cluster were firstly identified using FindAllMarkers function in Seurat R package by (logFC.threshold > 0.25, minPct > 0.1), then the marker genes with different cut-off were further studied and evaluated. Heatmaps were created by Seurat Package using the mean expression of markers in each cluster per time point. Declarations Conflicts of Interest Statement The authors have declared that no conflict of interest exists. Availability of data The single cell RNAseq raw and processed files are available at NCBI Gene Expression Omnibus and the accession number is xxxxx. Statistics . Statistical analysis was performed using an unpaired Student’s t test, 1- or 2- way ANOVA with Sidak’s or Tukey’s correction as applicable in GraphPad Prism (version 8.4.1). A P value of <0.05 was considered as statistically significant. * P < 0.05; ** P <0.01; *** P < 0.001; **** P < 0.0001. Data are represented as Mean + SEM. Acknowledgements This work was supported by National Institutes of Health (NIH) investigator- AI111943, AI123047, OD031898 and AI170148, and institutional- grants OD010442, AI168439, AI161943, OD028732, OD032443 and CPRIT Core Facility Award (RP220662). SIVmac 239 was graciously provided by Drs Preston Marx and Nick Manness, Tulane National Primate Research Center. SIV viral load assays were performed by the Nonhuman Primate Core Virology Laboratory for AIDS Research and Development, Division of AIDS, NIAID. PMPA and FTC were provided by Gilead Sciences and DTG was provided by Viiv Healthcare. Data was generated in the Genome Sequencing Facility, which is supported by UT Health San Antonio, CA054174. Author contributions RS, JR, DK designed the study. RS and BS performed sample collection and processing. VS, EJ performed macaque necropsies and pathology studies. SHU was the attending veterinarian for the study. XA performed the PET/CT and related analysis. RS, ZL, YZ and DK performed the data analysis. ZL performed quality control of BAL cells, 10x scRNA-seq and NGS workflow. SAK, JR helped RS and DK in writing of the manuscript. References Wong, N.S., et al., A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients . Sci Rep, 2019. 9(1): p. 10093. Dravid, A., et al., Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India . BMC Infect Dis, 2019. 19(1): p. 714. Ahmed, A., et al., Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study . BMJ Open, 2018. 8(2): p. e016961. Liu, E., et al., Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy . Aids, 2015. 29(11): p. 1391–9. Lawn, S.D., et al., Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control . Aids, 2006. 20(12): p. 1605–12. Suthar, A.B., et al., Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis . PLoS Med, 2012. 9(7): p. e1001270. Adhikari, N., et al., Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal . PLoS One, 2022. 17(1): p. e0262720. Danel, C., et al., A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa . N Engl J Med, 2015. 373(9): p. 808–22. Badje, A., et al., Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial . Lancet Glob Health, 2017. 5(11): p. e1080-e1089. Rangaka, M.X., et al., Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial . Lancet, 2014. 384(9944): p. 682–90. Semitala, F.C., et al., Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial . PLoS Med, 2021. 18(12): p. e1003875. Chaisson, L.H., et al., Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine . Aids, 2023. 37(7): p. 1097–1101. Sharan, R., et al., Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs . J Clin Invest, 2022. 132(18). Bucsan, A.N., et al., Mechanisms of reactivation of latent tuberculosis infection due to SIV co-infection . J Clin Invest, 2019. Sharan, R., et al., Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model . J Clin Invest, 2022. 132(3). Kuroda, M.J., et al., High Turnover of Tissue Macrophages Contributes to Tuberculosis Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques . J Infect Dis, 2018. 217(12): p. 1865–1874. Foreman, T.W., et al., CD4 + T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection . Proc Natl Acad Sci U S A, 2016. 113(38): p. E5636-44. Sharan, R., et al., Chronic Immune Activation in TB/HIV Co-infection . Trends Microbiol, 2020. 28(8): p. 619–632. Ganatra, S.R., et al., Anti-retroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV co-infection model . J Clin Invest, 2020. Ganatra, S.R., et al., Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model . J Clin Invest, 2020. 130(10): p. 5171–5179. Macatangay, B.J.C., et al., T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy . Aids, 2020. 34(1): p. 15–24. Day, C.L., et al., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression . Nature, 2006. 443(7109): p. 350–4. Shanmugasundaram, U., et al., Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment . JCI Insight, 2020. 5(14). Arlehamn, C.L., et al., Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features . J Immunol, 2014. 193(6): p. 2931–40. Gosselin, A., et al., Peripheral blood CCR4 + CCR6 + and CXCR3 + CCR6 + CD4 + T cells are highly permissive to HIV-1 infection . J Immunol, 2010. 184(3): p. 1604–16. Dawson, R., et al., Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis . PLoS One, 2009. 4(9): p. e6984. Schwander, S. and K. Dheda, Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection . Am J Respir Crit Care Med, 2011. 183(6): p. 696–707. Mehra, S., et al., Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus . J Med Primatol, 2011. 40(4): p. 233–43. Li, G., et al., Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8 + T effector levels in Han Chinese pulmonary TB patients . Microbes Infect, 2020. 22(3): p. 119–126. Allie, N., et al., Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection . Sci Rep, 2013. 3: p. 1809. Olsen, A., et al., Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines . mBio, 2016. 7(3). Mehta, A.K., D.T. Gracias, and M. Croft, TNF activity and T cells . Cytokine, 2018. 101: p. 14–18. Pollock, K.M., et al., T-cell immunophenotyping distinguishes active from latent tuberculosis . J Infect Dis, 2013. 208(6): p. 952–68. Harari, A., et al., Dominant TNF-α + Mycobacterium tuberculosis-specific CD4 + T cell responses discriminate between latent infection and active disease . Nat Med, 2011. 17(3): p. 372–6. Ogongo, P., et al., High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL17 against M. tuberculosis antigen . bioRxiv, 2024. Afriyie-Asante, A., et al., Mycobacterium tuberculosis Exploits Focal Adhesion Kinase to Induce Necrotic Cell Death and Inhibit Reactive Oxygen Species Production . Front Immunol, 2021. 12: p. 742370. Park, H.E., et al., Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis? Front Immunol, 2021. 12: p. 703060. Moreira-Teixeira, L., et al., Type I interferons in tuberculosis: Foe and occasionally friend . J Exp Med, 2018. 215(5): p. 1273–1285. Esaulova, E., et al., The immune landscape in tuberculosis reveals populations linked to disease and latency . Cell Host Microbe, 2020. Scott, N.R., et al., S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis . J Clin Invest, 2020. 130(6): p. 3098–3112. Berry, M.P., et al., An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis . Nature, 2010. 466(7309): p. 973–7. Ahmed, M., et al., Immune correlates of tuberculosis disease and risk translate across species . Sci Transl Med, 2020. 12(528). Akter, S., et al., Mycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes . Cell Rep, 2022. 39(12): p. 110983. Esaulova, E., et al., The immune landscape in tuberculosis reveals populations linked to disease and latency . Cell Host Microbe, 2021. 29(2): p. 165–178.e8. Martinson, N.A., et al., New regimens to prevent tuberculosis in adults with HIV infection . N Engl J Med, 2011. 365(1): p. 11–20. Sterling, T.R., et al., Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons . Aids, 2016. 30(10): p. 1607–15. Dooley, K.E., et al., Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial . Lancet HIV, 2020. 7(6): p. e401-e409. Kaushal, D., et al., The non-human primate model of tuberculosis . J Med Primatol, 2012. 41(3): p. 191–201. Scanga, C.A. and J.L. Flynn, Modeling tuberculosis in nonhuman primates . Cold Spring Harb Perspect Med, 2014. 4(12): p. a018564. Flynn, J.L., et al., Immunology studies in non-human primate models of tuberculosis . Immunol Rev, 2015. 264(1): p. 60–73. Gideon, H.P., et al., Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control . Immunity, 2022. 55(5): p. 827–846.e10. Counoupas, C. and J.A. Triccas, The generation of T-cell memory to protect against tuberculosis . Immunol Cell Biol, 2019. 97(7): p. 656–663. Gehad, A., et al., A primary role for human central memory cells in tissue immunosurveillance . Blood Adv, 2018. 2(3): p. 292–298. Robert, M. and P. Miossec, Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor . Cell Mol Immunol, 2021. 18(7): p. 1644–1651. Mundra, A., et al., Pathogenicity of Type I Interferons in Mycobacterium tuberculosis . Int J Mol Sci, 2023. 24(4). McNab, F., et al., Type I interferons in infectious disease . Nat Rev Immunol, 2015. 15(2): p. 87–103. Mayer-Barber, K.D. and B. Yan, Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses . Cell Mol Immunol, 2017. 14(1): p. 22–35. Moreira-Teixeira, L., et al., Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis . Nat Commun, 2020. 11(1): p. 5566. Xu, G., et al., Insights into battles between Mycobacterium tuberculosis and macrophages . Protein Cell, 2014. 5(10): p. 728–36. Apelbaum, A., et al., Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands . Mol Cell Biol, 2013. 33(4): p. 800–14. Prezzemolo, T., et al., Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis . Front Immunol, 2014. 5: p. 180. Lawn, S.D., A. Gupta, and R. Wood, Assessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential. Aids, 2012. 26(13): p. 1730-1; author reply 1728-9. Gupta, A., et al., Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community . PLoS One, 2012. 7(3): p. e34156. Manca, C., et al., Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates . J Immunol, 1999. 162(11): p. 6740–6. Bucşan, A.N., et al., Mechanisms of reactivation of latent tuberculosis infection due to SIV coinfection . J Clin Invest, 2019. 129(12): p. 5254–5260. Mehra, S., et al., The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs . J Infect Dis, 2012. 205(8): p. 1203–13. Mehra, S., et al., Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis . J Infect Dis, 2013. 207(7): p. 1115–27. Kaushal, D., et al., Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis . Nat Commun, 2015. 6: p. 8533. Singh, D.K., et al., Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets . Nat Microbiol, 2021. 6(1): p. 73–86. Stammes, M.A., et al., Recommendations for Standardizing Thorax PET-CT in Non-Human Primates by Recent Experience from Macaque Studies . Animals (Basel), 2021. 11(1). Mattila, J.T., et al., Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells . J Immunol, 2017. 199(2): p. 806–815. Sakai, S., et al., Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates . Mucosal Immunol, 2021. 14(5): p. 1055–1066. Li, Q., et al., A technique to simultaneously visualize virus-specific CD8 + T cells and virus-infected cells in situ . J Vis Exp, 2009(30). Alexandrov, L.B., et al., The repertoire of mutational signatures in human cancer . Nature, 2020. 578(7793): p. 94–101. Additional Declarations There is NO Competing Interest. Supplementary Files SupplementaryTable1.tif Suppl Table 1 SupplementaryTable2.tif Suppl Table 2 SupplementaryTable3.tif Suppl Table 3 SupplementaryFigure1.tif S1 SupplementaryFigure2.tif S2 SupplementaryFigure3.tif S3 SupplementaryFigure4.tif S4 SupplementaryFigure5.tif S4 SupplementaryFigure6.tif S6 SupplementaryFigure7.tif S7 SupplementaryFigure8.tif S8 SupplementaryFigure9.tif S9 Cite Share Download PDF Status: Published Journal Publication published 12 Dec, 2025 Read the published version in Nature Communications → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4908400","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":341014227,"identity":"8ca9f8d8-6de9-41dc-8c8d-19f3621027b0","order_by":0,"name":"Riti Sharan","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Riti","middleName":"","lastName":"Sharan","suffix":""},{"id":341014228,"identity":"561ac9a1-0655-4720-bf98-cc62e7710043","order_by":1,"name":"Yi Zou","email":"","orcid":"","institution":"UTHSCSA","correspondingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Zou","suffix":""},{"id":341014233,"identity":"d58bdbc2-507c-4d05-9881-3de15d3e6380","order_by":2,"name":"Zhao Lai","email":"","orcid":"","institution":"The University of Texas Health San Antonio","correspondingAuthor":false,"prefix":"","firstName":"Zhao","middleName":"","lastName":"Lai","suffix":""},{"id":341014234,"identity":"2fe062b2-7bda-44ce-8bc5-09463db265a8","order_by":3,"name":"Bindu Singh","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Bindu","middleName":"","lastName":"Singh","suffix":""},{"id":341014235,"identity":"4800ccef-d604-47d9-a249-39e9a1b8bb85","order_by":4,"name":"Vinay Shivanna","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Vinay","middleName":"","lastName":"Shivanna","suffix":""},{"id":341014236,"identity":"8a1f3e07-d48a-4332-b78d-547ecea36fa7","order_by":5,"name":"Edward Dick, Jr","email":"","orcid":"","institution":"Southwest National Primate Research Center","correspondingAuthor":false,"prefix":"","firstName":"Edward","middleName":"","lastName":"Dick","suffix":"Jr"},{"id":341014237,"identity":"816b1e4b-ea8c-49c7-84d5-402a53f3b6f0","order_by":6,"name":"Shannan Hall-Ursone","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Shannan","middleName":"","lastName":"Hall-Ursone","suffix":""},{"id":341014238,"identity":"ba95fd27-b92b-499d-8bac-d49c4d322ffe","order_by":7,"name":"Shabaana Khader","email":"","orcid":"https://orcid.org/0000-0002-9545-4982","institution":"University of Chicago","correspondingAuthor":false,"prefix":"","firstName":"Shabaana","middleName":"","lastName":"Khader","suffix":""},{"id":341014239,"identity":"46370e9c-d790-4941-bed5-4fe2e31c0e06","order_by":8,"name":"Smriti Mehra","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Smriti","middleName":"","lastName":"Mehra","suffix":""},{"id":341014240,"identity":"4f225a4c-e52c-4c21-b409-934fb9da6ef9","order_by":9,"name":"Xavier Alvarez","email":"","orcid":"","institution":"Texas Biomedical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Xavier","middleName":"","lastName":"Alvarez","suffix":""},{"id":341014241,"identity":"1a56127b-4563-4706-ab09-52a2b46e46a3","order_by":10,"name":"Jyothi Rengarajan","email":"","orcid":"https://orcid.org/0000-0003-1241-4705","institution":"Emory University","correspondingAuthor":false,"prefix":"","firstName":"Jyothi","middleName":"","lastName":"Rengarajan","suffix":""},{"id":341014226,"identity":"9ac3f8e5-b993-4216-b367-3b6e140fe434","order_by":11,"name":"Deepak Kaushal","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA60lEQVRIiWNgGAWjYDCCM0DM2MAgw8/AwMaQABI5QKQWHsk2krUYHANqYSBGC9+Zw88kf+6w4zG+32P24EHFNjm+A8zHPn7Bo0XybJuZNO+ZZB6zY2zpBglnbhtLHmBLni2DR4vBeQYzacY2ZqAW5mMSiW23Ezcc4DFmlsCrhf2b5M+2eh7jNsY2kJZ6wlrO9phJ8LYd5jFgg9iSYADUwvgBn1/OnCm25m07ziNxLA3sF8OZh9mSmfHoAIZY+sabP9uq5fibz5g9/FFxW57vePNhxh/49GACoBXMPKRpAQJSbRkFo2AUjILhDQBaXU/bNwWqIAAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0003-3521-1257","institution":"Southwest National Primate Research Center, Texas Biomedical Research Institute","correspondingAuthor":true,"prefix":"","firstName":"Deepak","middleName":"","lastName":"Kaushal","suffix":""}],"badges":[],"createdAt":"2024-08-13 16:05:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4908400/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4908400/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41467-025-67188-4","type":"published","date":"2025-12-12T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":63258453,"identity":"dff00cf1-24dc-40ce-86e1-a8ad2c11b15b","added_by":"auto","created_at":"2024-08-26 08:38:24","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":2231756,"visible":true,"origin":"","legend":"\u003cp\u003eConcurrent treatment with cART and 3HP improves clinical and microbiological attributes of\u003cem\u003e Mtb\u003c/em\u003e/SIV co-infection\u003cem\u003e.\u003c/em\u003e (A) Study outline. (B) Serum CRP levels. Bacterial burden (log\u003csub\u003e10\u003c/sub\u003eCFU/g or log\u003csub\u003e10\u003c/sub\u003eCFU/mL) was determined in (C) lung, (D) lung granulomas, (E) bronchoalveolar lavage (BAL), (F) bronchial lymph nodes (BrLN) at necropsy by homogenizing the tissues and plating on agar plates. (G) Viral loads in plasma of cART and cART+3HP-treated RMs were measured longitudinally throughout the study. (H) Blood biochemistry for serum albumin/globulin (A/G) (g/dL) ratio, aspartate aminotransferase or serum glutamic-oxaloacetic transaminase (ALT/SGOT) (units per liter of serum), blood urea nitrogen/creatinine (BUN/creat) (µmol/L) ratio, and alkaline phosphatase (Alk phos) (units per liter), at week 24 after TB infection or 1-week after treatment completion for both cART and cART+3HP-treated groups. (I) To determine the impact of cART+3HP on lung pathology, lung tissue was collected at necropsy and stained with H\u0026amp;E to study the cellular and granulomatous pathology in LTBI (\u003cem\u003en \u003c/em\u003e= 4), cART naive (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 8), cART (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 4), and cART+3HP (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 6). Scale bars: 500µm. (J) Percentage of lung involvement was calculated by a board-certified pathologist by quantification of the number of lesions per lobe. (K) Representative PET scans of cART+3HP treated RM at week 6 (LTBI), week 12 (LTBI+SIV), week 16 (LTBI+SIV+cART+3HP) and week 22 (end of cART+3HP treatment). Significance was determined in LTBI (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 4), cART naive (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 8), cART (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 4), and cART+3HP (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 6) using 1-way ANOVA with Tukey’s multiple-comparison test. *\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.05; **\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01; ***\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001; ****\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.0001. Data are presented as mean ± SEM.\u003c/p\u003e","description":"","filename":"Figure1Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/7220ad1e7cb07939adc7ef01.png"},{"id":63258454,"identity":"a5f6f250-6449-4901-9b31-49a9ab2f5a7f","added_by":"auto","created_at":"2024-08-26 08:38:24","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1404885,"visible":true,"origin":"","legend":"\u003cp\u003eTreatment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs with cART+3HP increases migration of T\u003csub\u003eH17\u003c/sub\u003e and T\u003csub\u003eH1*\u003c/sub\u003e cells into pulmonary compartment compared to cART naïve RMs. We measured percentages of CD4\u003csup\u003e+\u003c/sup\u003e T cells in (A) BAL and (B) lung, and percentages of CD8\u003csup\u003e+\u003c/sup\u003e T cells in (C) BAL and (D) in LTBI (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 4), cART naive (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 8), cART (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 4), and cART+3HP (\u003cem\u003en\u003c/em\u003e\u0026nbsp;= 6) RMs to measure immune reconstitution in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected. To study impact of cART+3HP on immune activation, we measured the percentages of (E) BAL HLA-DR\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells, (F) BAL CD69\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells, and (G) PD-1\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells at peak viremia (week 11 post-\u003cem\u003eMtb\u003c/em\u003e infection or 2 weeks post SIV co-infection of LTBI) and at necropsy. We determined T\u003csub\u003eH17\u003c/sub\u003e and T\u003csub\u003eH1*\u003c/sub\u003e response in pulmonary and peripheral compartments by measuring percentage of (H) BAL CCR6\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells, (I) BAL CXCR3\u003csup\u003e+\u003c/sup\u003eCCR6\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003eT cells and (J) WB CXCR3\u003csup\u003e+\u003c/sup\u003eCCR6\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells) at peak viremia (week 11 post-\u003cem\u003eMtb\u003c/em\u003e infection or 2 weeks post SIV co-infection of LTBI) and at necropsy. (K) We performed immunohistochemistry to study impact of cART+3HP treatment on macrophage turnover by staining for BrDU+ nuclei (green, indicated with white arrows) of macrophages (CD163+CD68+, red) per µm\u003csup\u003e2 \u003c/sup\u003eof lung sections of cART naïve, cART and cART+3HP treated RMs. (L) The images were analyzed using HALO software and captured on Axio Scan Z1. Significance was determined using 2-tailed Student’s t test. *P \u0026lt; 0.05.\u003c/p\u003e","description":"","filename":"Figure2Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/09d5b1291184bc078f9838fa.png"},{"id":63258459,"identity":"d9581937-4dfd-42af-b7c3-5d620436d000","added_by":"auto","created_at":"2024-08-26 08:38:25","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":599055,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003ePoor recovery of effector memory T cells in RMs treated with cART or cART+3HP. \u003c/em\u003eWe immunophenotyped the pulmonary CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u003csup\u003e+\u003c/sup\u003e T cells in cART or cART+3HP treated RMs into CD\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e and CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e populations. Percentage of (A) BAL CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e, (B) BAL CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e, (C) BAL CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e and (D) BAL CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e were measured in BAL of cART+3HP treated RMs at pre-infection, weeks 3, 11 and 24 post \u003cem\u003eMtb\u003c/em\u003e-infection. We compared the percentage of (E) BAL CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e, (F) lung CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e, (G) BAL CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e, (H) lung CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e, (I) BAL CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e, (J) lung CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e, (K) BAL CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e, (L) lung CD8\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e in cART versus cART+3HP treated RMs at necropsy. Significance was determined using 1-way ANOVA with Sidak’s or Tukey’s correction as applicable. *\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.05; **\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01; ***\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001; ****\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.0001. Data are presented as mean ± SEM.\u003c/p\u003e","description":"","filename":"Figure3Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/2617352bddb0010a15078738.png"},{"id":63258457,"identity":"062479bc-d85a-4791-be3b-d4fe0bf85773","added_by":"auto","created_at":"2024-08-26 08:38:24","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1676261,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003ecART+3HP increases Mtb-specific T\u003c/em\u003e\u003csub\u003e\u003cem\u003eH1\u003c/em\u003e\u003c/sub\u003e\u003cem\u003e/T\u003c/em\u003e\u003csub\u003e\u003cem\u003eH17\u003c/em\u003e\u003c/sub\u003e\u003cem\u003e response in pulmonary compartment of Mtb/SIV co-infected RMs.\u003c/em\u003e Percentage of CD4\u003csup\u003e+\u003c/sup\u003eIFNg\u003csup\u003e+\u003c/sup\u003e T cells in response to (A) ESAT-6/CFP-10, (B) \u003cem\u003eMtb\u003c/em\u003e CW, CD4\u003csup\u003e+\u003c/sup\u003eTNFa\u003csup\u003e+ \u003c/sup\u003eT cells in response to (C) ESAT-6/CFP-10, (D) \u003cem\u003eMtb\u003c/em\u003e CW and CD4\u003csup\u003e+\u003c/sup\u003eIL-17\u003csup\u003e+\u003c/sup\u003e T cells in response to (E) ESAT-6/CFP-10 and (F) \u003cem\u003eMtb\u003c/em\u003e CW were measured in BAL at weeks 5, 11 and necropsy in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with cART (\u003cem\u003en\u003c/em\u003e = 4) or cART+3HP (\u003cem\u003en \u003c/em\u003e= 6). Percentage of CD4\u003csup\u003e+ \u003c/sup\u003eT cells expressing either IFNg, TNFa or IL17 was measured in lung at necropsy in response to (G) ESAT=6/CFP-10 and (H) \u003cem\u003eMtb\u003c/em\u003e CW. Significance was determined using 1-way ANOVA with Sidak’s or Tukey’s correction as applicable. *\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.05; **\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.01; ***\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.001; ****\u003cem\u003eP\u003c/em\u003e\u0026nbsp;\u0026lt; 0.0001. Data are presented as mean ± SEM.\u003c/p\u003e","description":"","filename":"Figure4Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/e9ede916c424c1995ac737bd.png"},{"id":63259236,"identity":"76b8019a-7a78-4805-8ec1-d753c0c21b5c","added_by":"auto","created_at":"2024-08-26 08:46:24","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1739019,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eSingle cell transcriptomic signature in pulmonary compartment of Mtb/SIV co-infected RMs. \u003c/em\u003e(A) Study outline for BAL sample collection from \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with 12-weeks, once oral, cART+3HP (\u003cem\u003en\u003c/em\u003e = 6). (B) Quality control of BAL cells in terms of percent viability using automated cell countess, manual counts using trypan blue and microscopic evaluation. (C) BAL cells are then loaded onto Chromium controller (10x Genomics) to generate single-cell beads in emulsion. (D) Uniformed Manifold Approximation and Projection (UMAP) clustering to identify transcriptionally distinct clusters at weeks 5, 11, 13 and necropsy. (E) The total number of transcripts detected within each cell at weeks 5, 11, 13 and necropsy. (F) The total number of molecules detected within each cell at weeks 5, 11, 13 and necropsy.\u003c/p\u003e","description":"","filename":"Figure5Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/5af6437e1ccaf53e42bc8bb1.png"},{"id":63259952,"identity":"59850ed6-9d3a-4c58-87d7-1d8488f1c4f1","added_by":"auto","created_at":"2024-08-26 08:54:25","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":500754,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eT\u003c/em\u003e\u003csub\u003e\u003cem\u003eH1\u003c/em\u003e\u003c/sub\u003e\u003cem\u003e/T\u003c/em\u003e\u003csub\u003e\u003cem\u003eH17\u003c/em\u003e\u003c/sub\u003e\u003cem\u003e signature in cART+3HP treated RMs\u003c/em\u003e. Heatmap analysis of genes associated with T\u003csub\u003eH1\u003c/sub\u003e, T\u003csub\u003eH2\u003c/sub\u003e and T\u003csub\u003eH17\u003c/sub\u003e response in (A) lymphoid clusters and (B) myeloid clusters from BAL of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with cART+3HP at weeks 5, 11, 13 and necropsy (n = 6).\u003c/p\u003e","description":"","filename":"Figure6Concurrentpaper.png","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/a76cf851f85d01a54e490706.png"},{"id":100296079,"identity":"6753c25a-41fe-4127-8f72-0b786c029a97","added_by":"auto","created_at":"2026-01-15 08:10:30","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":10099727,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/656e73fe-d15b-4df9-bc49-d7fea8ac4741.pdf"},{"id":63259237,"identity":"abd044a3-56bf-44ad-bd85-cb177cff6a26","added_by":"auto","created_at":"2024-08-26 08:46:24","extension":"tif","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"Suppl Table 1","description":"","filename":"SupplementaryTable1.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/6789f0a67a5abe486041bfe6.tif"},{"id":63259954,"identity":"daa1f143-b0fe-479f-87c2-e8f79a590f29","added_by":"auto","created_at":"2024-08-26 08:54:25","extension":"tif","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"Suppl Table 2","description":"","filename":"SupplementaryTable2.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/f361bb1d0cdebb79f23a941c.tif"},{"id":63260520,"identity":"64414048-8f59-4d1e-a949-6182bea56847","added_by":"auto","created_at":"2024-08-26 09:02:25","extension":"tif","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"Suppl Table 3","description":"","filename":"SupplementaryTable3.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/8bb834053c5478a37521f500.tif"},{"id":63258466,"identity":"ae4eec39-0b56-46c8-b47a-52a0c21db3ca","added_by":"auto","created_at":"2024-08-26 08:38:25","extension":"tif","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"\u003cp\u003eS1\u003c/p\u003e","description":"","filename":"SupplementaryFigure1.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/218558b0ff936b3a2a4d40b0.tif"},{"id":63259238,"identity":"20487267-c4f5-4dc8-b933-85f551161701","added_by":"auto","created_at":"2024-08-26 08:46:25","extension":"tif","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S2","description":"","filename":"SupplementaryFigure2.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/196fb716c4e754412018ef27.tif"},{"id":63258462,"identity":"9765551d-96fe-41d5-8a92-e9e01ef537d7","added_by":"auto","created_at":"2024-08-26 08:38:25","extension":"tif","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"\u003cp\u003eS3\u003c/p\u003e","description":"","filename":"SupplementaryFigure3.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/3b9091cc8fd4eceac7e2d2dd.tif"},{"id":63258470,"identity":"62554cb0-2c89-4c98-a3ac-8dc5c9c84d23","added_by":"auto","created_at":"2024-08-26 08:38:26","extension":"tif","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S4","description":"","filename":"SupplementaryFigure4.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/34169ab7e6d7a1efb832bf04.tif"},{"id":63259239,"identity":"00940efe-3b52-4787-9f0c-5eff9670de04","added_by":"auto","created_at":"2024-08-26 08:46:25","extension":"tif","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S4","description":"","filename":"SupplementaryFigure5.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/68e9e8e4887aecc4139f600f.tif"},{"id":63258471,"identity":"f12a9a82-5bef-4e20-90d8-c3c44192253a","added_by":"auto","created_at":"2024-08-26 08:38:26","extension":"tif","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S6","description":"","filename":"SupplementaryFigure6.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/508293c267996b7652735d01.tif"},{"id":63258468,"identity":"5b62fd5a-5c3c-49d5-bd6f-3e44befbc185","added_by":"auto","created_at":"2024-08-26 08:38:25","extension":"tif","order_by":10,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S7","description":"","filename":"SupplementaryFigure7.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/ddbe09af926b0944b32804ad.tif"},{"id":63258467,"identity":"c33e02d8-0e2e-4f2b-bfaf-e33458d92b12","added_by":"auto","created_at":"2024-08-26 08:38:25","extension":"tif","order_by":11,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S8","description":"","filename":"SupplementaryFigure8.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/76dfac6cf49f68411478bb20.tif"},{"id":63259243,"identity":"794fd837-5eb7-4556-9432-ef30c2b03d37","added_by":"auto","created_at":"2024-08-26 08:46:25","extension":"tif","order_by":12,"title":"","display":"","copyAsset":false,"role":"supplement","size":25205140,"visible":true,"origin":"","legend":"S9","description":"","filename":"SupplementaryFigure9.tif","url":"https://assets-eu.researchsquare.com/files/rs-4908400/v1/1267ed84bd9bb579525c6540.tif"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCombinatorial antiretroviral therapy (cART) reduces the risk of reactivation of latent tuberculosis infection (LTBI) in humans [\u003cspan additionalcitationids=\"CR2 CR3\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLWH) [\u003cspan additionalcitationids=\"CR6\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Anti-tubercular treatment has been shown to reduce disease incidence by 30\u0026ndash;50%[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e] and is recommended for PLWH in high-burden countries. Observational studies in humans suggest that concurrent administration of cART and Isoniazid Preventive Therapy (IPT) for LTBI lowers the risk of developing TB compared to cART alone [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. A randomized double-blind placebo-controlled trial [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] showed that administering IPT in conjunction with cART resulted in significantly lower numbers of incident TB cases than cART plus placebo. Thus, concurrent cART\u0026thinsp;+\u0026thinsp;IPT leads to improved outcomes with clear protective effects and clinical benefit to HIV-infected individuals. Although the WHO recommends concurrent IPT and cART in TB-endemic settings, uptake remains poor and the immune mechanisms underlying the benefits of concurrent cART and IPT have not been defined. Another caveat of this approach has been a lack of completion of treatment regimen by majority of those who initiate the 6-month course of daily isoniazid while on cART. To enable treatment adherence and completion, the World Health Organization (WHO) recommended 12-dose weekly regimen of Isoniazid and Rifapentine (3HP) as a treatment-shortened option for treating TB. Concurrent administration of cART and 3HP was safe and well tolerated with over 95% completion rate [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. In our RM model of \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e (\u003cem\u003eMtb)\u003c/em\u003e/SIV co-infection, though 3HP effectively reduced persistent LTBI [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], it did not sterilize the lungs of a third of the treated RMs [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Recent work in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] shows that in addition to the depletion of CD4\u003csup\u003e+\u003c/sup\u003e T cells, HIV-driven chronic immune activation correlates with LTBI reactivation [\u003cspan additionalcitationids=\"CR15 CR16 CR17\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Though cART controls viral replication, it leads to insufficient reconstitution of protective CD4\u003csup\u003e+\u003c/sup\u003e T effector memory (T\u003csub\u003eEM\u003c/sub\u003e) responses in the lungs [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] and fails to rescue from virus-driven immune activation [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Administration of anti-tubercular therapy, concurrently with cART reduces reactivation significantly better than cART among individuals with LTBI [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. However, long-term sterilization of bacteria and immune reconstitution in the lungs has not been shown in these individuals.\u003c/p\u003e \u003cp\u003eIn this study, we leveraged our nonhuman primate (NHP) model of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection to study effect of simultaneous cART and 3HP treatment on immune responses to \u003cem\u003eMtb\u003c/em\u003e. Performing these studies in humans is virtually impossible due to lack of determination of timing of \u003cem\u003eMtb\u003c/em\u003e and HIV co-infections, verification of bacterial and viral loads and performance of invasive longitudinal studies to investigate the lung compartment. Our very low-dose aerosol infection NHP model recapitulates the spectrum of human lung pathological lesions, including LTBI and its reactivation to active TB by HIV [\u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. We carried out detailed studies of the immune responses by longitudinal sampling of blood and bronchoalveolar lavage (BAL) in the absence of cART as well as during and after cART and cART\u0026thinsp;+\u0026thinsp;3HP. Importantly, we investigated the functional capacity of antigen-specific T cell immunity in the lung microenvironment. Our findings clearly show that while cART and 3HP control viral and bacterial replication, respectively, there is partial immune reconstitution and with the reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cell exhibited highly impaired functional capabilities. In particular, skewed CD4\u003csup\u003e+\u003c/sup\u003e T effector memory responses persist despite concurrent cART and anti-TB treatment in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected macaques and the ongoing inflammation in the lung is not ameliorated. It is well known that PLHIV and TB remain at risk for progression due to subsequent infections or TB reactivation even after improved clinical and microbiological attributes. We conclude that persisting immune activation/inflammation are the mechanisms that cause this susceptibility. Clearly host directed therapies against immune activation and lung inflammation, adjunctive to TB therapy and cART must be developed to better treat PLHIV with TB.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cem\u003eConcurrent treatment with cART and 3HP improves clinical and microbiological attributes of Mtb/SIV co-infection\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eTo assess the impact of concurrent cART and 3HP therapy on LTBI reactivation in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection, we utilized 6 new RMs and reused published data from LTBI (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;4), cART -na\u0026iuml;ve coinfected RMs (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;8) and co-infected RMs treated with cART alone for 9 weeks (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;4) (refs 15, 19 and Supplemental Table\u0026nbsp;2). The study design is outlined in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA. All the RMs were infected with a low dose of \u003cem\u003eMtb\u003c/em\u003e (~\u0026thinsp;10 CFU deposited in the lungs) and subsequently with SIV (300 TCID\u003csub\u003e50\u003c/sub\u003e SIV\u003csub\u003emac239\u003c/sub\u003e, intravenous). Infection was confirmed by a positive tuberculin skin test at weeks 3 and 5 after \u003cem\u003eMtb\u003c/em\u003e infection. All study RMs developed LTBI infection characterized by less than 1 to 2 Log\u003csub\u003e10\u003c/sub\u003eCFU of \u003cem\u003eMtb\u003c/em\u003e in the bronchoalveolar lavage (BAL) at weeks 3, 5 and 7 post \u003cem\u003eMtb\u003c/em\u003e infection, serum C-reactive protein (CRP) of 5 \u0026micro;g/mL or lower (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB), and no significant change in percentage body temperature (Supplemental Fig.\u0026nbsp;1A) and body weight (Supplemental Fig.\u0026nbsp;1B) up to 9 weeks after \u003cem\u003eMtb\u003c/em\u003e infection. Upon establishment of latency, RMs were coinfected with 300 TCID\u003csub\u003e50\u003c/sub\u003e SIV\u003csub\u003emac239\u003c/sub\u003e via the intravenous route 9 weeks after \u003cem\u003eMtb\u003c/em\u003e infection [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. SIV infection was confirmed by measuring the plasma viral loads via reverse transcriptase quantitative PCR (RT-qPCR). The RMs were either treated with cART alone or cART\u0026thinsp;+\u0026thinsp;3HP, once weekly orally for 12 weeks (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA) and euthanized at treatment completion. Clinical, pathological and immunological response was compared in the 4 experimental groups: LTBI, cART na\u0026iuml;ve, cART and cART\u0026thinsp;+\u0026thinsp;3HP.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe RMs in cART\u0026thinsp;+\u0026thinsp;3HP group survived in good body condition with adequate body muscling and fat until the predetermined study endpoint. RMs in cART na\u0026iuml;ve group were humanely euthanized on prespecified endpoints starting as early as 2 weeks post SIV co-infection (Supplemental Fig.\u0026nbsp;1C). Elevated serum CRP levels associate with active TB and increase in bacterial burdens in NHPs [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. CRP levels in cART\u0026thinsp;+\u0026thinsp;3HP were significantly lower than cART na\u0026iuml;ve (\u003cem\u003eP\u0026thinsp;\u0026lt;\u0026thinsp;0.0001\u003c/em\u003e) and cART treated RMs (\u003cem\u003eP\u0026thinsp;\u0026lt;\u0026thinsp;0.001\u003c/em\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). More importantly, the CRP levels in cART\u0026thinsp;+\u0026thinsp;3HP RMs was not significantly different from LTBI RMs (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.44). To determine the impact of cART\u0026thinsp;+\u0026thinsp;3HP on bacterial burden, BAL fluid, lungs, bronchial lymph nodes and lung granulomas were plated on 7H11 agar plates as previously described [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. 5 out of 6 RMs in cART\u0026thinsp;+\u0026thinsp;3HP group had no detectable bacterial burden in lung collected at necropsy, compared to just 1 out of four cART-treated and 2 out of 14 cART-naive RMs and both differences were statistically significant (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC). Thus, the cART\u0026thinsp;+\u0026thinsp;3HP group behaved comparable to the LTBI (SIV uninfected) group with 87.5% and 75% of the lung samples being sterile respectively in these groups. All 6 RMs in cART\u0026thinsp;+\u0026thinsp;3HP group were devoid of detectable bacilli in lung granulomas (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD), BAL (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE) and bronchial lymph nodes (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF) at necropsy. Additionally, the bacterial burden in cART\u0026thinsp;+\u0026thinsp;3HP RMs was significantly lower than cART treated RMs in lung (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.01\u003c/em\u003e), lung granulomas (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.001\u003c/em\u003e) and bronchial lymph node (\u003cem\u003eP\u0026thinsp;\u0026lt;\u0026thinsp;0.0001\u003c/em\u003e). In contrast 81% RMs harbored bacilli in lung granulomas and 100% of study animals had detectable bacilli in bronchial lymph nodes when treated with cART alone (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD and \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003eTo evaluate the efficacy of cART regimen in presence of 3HP treatment, viral loads were measured in the plasma of all 6 RMs and compared with cART treated RMs at pre-determined time points post cART initiation (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). There was no significant difference in the rates of decay of the viral loads in either group. Thus, 3HP did not alter the efficacy of cART in controlling viral replication. We also studied cytotoxicity markers in blood to determine safety of administering cART\u0026thinsp;+\u0026thinsp;3HP relative to untreated and 3HP treated cohorts from archived samples. We did not observe any significant change in the levels of serum albumin/globulin (A/G) (g/dL) ratio, aspartate aminotransferase or serum glutamic-oxaloacetic transaminase (ALT/SGOT) (units per liter of serum), blood urea nitrogen/creatinine (BUN/creat) (\u0026micro;mol/L) ratio, and alkaline phosphatase (Alk phos) (units per liter), at week 24 after TB infection or 1 \u0026ndash; week after treatment completion (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eH) in untreated, 3HP treated and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. To determine the impact of cART\u0026thinsp;+\u0026thinsp;3HP treatment on the lung cellular and granulomatous pathology, lung tissue sections collected at necropsy were stained with hematoxylin and eosin (H\u0026amp;E) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eI) and findings analyzed by board-certified (Dipl, American College of Veterinary Pathologists) pathologists. The pathological findings correlated with the clinical and microbiological observations. There were a few, scattered, non-necrotizing and caseous granulomas in the lung lobes of approximately 0.5\u0026ndash;1 cm in size in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. There were rare, small aggregates of lymphocytes and macrophages in some lung sections. A single RM demonstrated multifocal accumulations of lymphocytes and non-necrotizing active granulomas in the liver. Overall, hilar, bronchial lymph nodes, spleen and other tissues were observed to have normal pathology comparable to LTBI only controls. cART\u0026thinsp;+\u0026thinsp;3HP RMs demonstrated significant decrease in percentage lung involvement in pathology compared to cART and cART na\u0026iuml;ve RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eJ). Overall, lung of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs harbored less lesions compared to cART-na\u0026iuml;ve RMs. Lung of cART na\u0026iuml;ve and cART alone treated RMs showed numerous large granulomas with necrotic cores. Thus, administration of cART\u0026thinsp;+\u0026thinsp;3HP is safe, efficacious in controlling bacterial burden and improved pathology compared to cART treated RMs.\u003c/p\u003e \u003cp\u003eWe performed Positron Emission Tomography with Computed Tomography (PET/CT) to study lung lesions in 3 of the 6 RMs at weeks 6 (LTBI), 12 (LTBI\u0026thinsp;+\u0026thinsp;SIV co-infection, one week post cART\u0026thinsp;+\u0026thinsp;3HP initiation), 16 (4 weeks post cART\u0026thinsp;+\u0026thinsp;3HP initiation) and 22 (10 weeks post cART\u0026thinsp;+\u0026thinsp;3HP initiation) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eK). The lung lesions in all RMs remained stable, i.e., no or minimal progression in size and architecture at week 6 after infection, confirming LTBI (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eK). All three RMs that were scanned showed significant increase (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.01) 18F-fluorodeoxyglucose (18F-FDG) uptake in lung upon SIV co-infection and 1 week of cART\u0026thinsp;+\u0026thinsp;3HP treatment at week 12 post \u003cem\u003eMtb\u003c/em\u003e infection indicating progression of TB pathology (Supplementary Fig.\u0026nbsp;1E). Scans at week 16 post \u003cem\u003eMtb\u003c/em\u003e infection (4 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment) showed decreased 18F-FDG uptake, though the decrease was not significant. We did not observe a further increase in volume of lung lesions (Supplementary Fig.\u0026nbsp;1D) or uptake of 18F-FDG (Supplementary Fig.\u0026nbsp;1E) at week 22 post \u003cem\u003eMtb\u003c/em\u003e infection (10 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment). PET/CT results therefore demonstrate a significant decrease in volume of lesions but not in their metabolic potential post cART\u0026thinsp;+\u0026thinsp;3HP treatment, suggesting that concurrent treatment led to a progressively increased resolution of caseous lesions that had been formed post SIV co-infection (week 12) but did not reduce the ongoing inflammation in the few remaining lesions.\u003c/p\u003e \u003cp\u003e \u003cem\u003eImmune reconstitution by cART\u0026thinsp;+\u0026thinsp;3HP in pulmonary compartment of Mtb/SIV co-infected RMs\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eImmunophenotyping of T cells was performed to assess both the extent and the quality of immune reconstitution by cART\u0026thinsp;+\u0026thinsp;3HP relative to cART in pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs. We have earlier demonstrated only partial restoration of depleted CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA) and lung (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB) after 12 weeks of cART in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs, with significantly lower frequencies in lung tissue than those in the LTBI animals. 12 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cell frequency in BAL to comparable levels of LTBI (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA) but not in lung, where the CD4\u003csup\u003e+\u003c/sup\u003e T cell frequency remained significantly lower than LTBI control (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB) (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021). A significantly increased percentage of CD8\u003csup\u003e+\u003c/sup\u003e T cells was observed in BAL (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC) of cART\u0026thinsp;+\u0026thinsp;3HP RMs compared to cART treated RMs (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.04\u003c/em\u003e) but not in lung (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD). The percentage of CD8\u003csup\u003e+\u003c/sup\u003e T cells were not significantly different in lung of LTBI, cART and cART\u0026thinsp;+\u0026thinsp;3HP treated, \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs. We have previously shown that chronic immune activation drives LTBI reactivation upon SIV co-infection in RMs [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. To assess the impact of cART\u0026thinsp;+\u0026thinsp;3HP on T cell activation, we studied expression of HLA-DR and CD69 on CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL at week 11 post \u003cem\u003eMtb\u003c/em\u003e infection (or 2 weeks post SIV co-infection, prior to initiation of cART\u0026thinsp;+\u0026thinsp;3HP) and at necropsy (end of 12 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment) in all 4 study groups. All \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected groups exhibited increased frequencies of HLA-DR\u003csup\u003e+\u003c/sup\u003e- and CD69\u003csup\u003e+\u003c/sup\u003e- CD4\u003csup\u003e+\u003c/sup\u003e T cells at week 11 (peak viremia) compared to the LTBI group (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eE, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eF). cART\u0026thinsp;+\u0026thinsp;3HP effectively reduced the percentage of CD4\u003csup\u003e+\u003c/sup\u003e T cells expressing HLA-DR and CD69 compared to cART na\u0026iuml;ve RMs, but not to the levels seen in LTBI or cART treated RMs. The increased activation of CD4\u003csup\u003e+\u003c/sup\u003e T cells may be attributed to tuberculosis-immune reconstitution inflammatory syndrome (TB-IRIS) with concurrent cART\u0026thinsp;+\u0026thinsp;3HP. High expression of PD-1 marker on T cells is often associated with increased exhaustion and T cell dysfunction in chronic infections such as HIV despite cART [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. To study the impact of cART\u0026thinsp;+\u0026thinsp;3HP on T cell exhaustion in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection, we determined the percentage T cells expressing PD-1 in BAL cells at week 11 (peak viremia) and necropsy (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eG). cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs demonstrated significantly higher percentage of PD-1\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells compared to LTBI RMs at necropsy. Addition of 3HP to cART did not alleviate T cell exhaustion in pulmonary compartment as seen by no significant difference in PD-1 expressing CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL between cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eG). This was in spite the fact that virtually no detectable \u003cem\u003eMtb\u003c/em\u003e and SIV were present at the end of the protocol in the concurrently treated RMs. Overall, we conclude that cART\u0026thinsp;+\u0026thinsp;3HP fails to control immune activation post SIV co-infection of LTBI leading to exhaustion of CD4\u003csup\u003e+\u003c/sup\u003e T cells in pulmonary compartment. We hypothesize that the duration and magnitude of immune activation dictates the incapability of T cells to elaborate the usual array of functional effector responses in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection. It is important to note that increased turnover is not observed in the macrophages (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eK and \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eL). A significantly lower (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) percentage of macrophage turnover was observed in the lungs of RMs treated with cART\u0026thinsp;+\u0026thinsp;3HP compared to cART and cART na\u0026iuml;ve RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eL). A higher number of BrDU\u003csup\u003e+\u003c/sup\u003e nuclei (green) within macrophages (red) as indicated by white arrows was seen in lung of cART na\u0026iuml;ve and cART treated RMs but was absent in lung of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eK).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe further studied the impact of cART\u0026thinsp;+\u0026thinsp;3HP on T\u003csub\u003eH17\u003c/sub\u003e and T\u003csub\u003eH1*\u003c/sub\u003e phenotypes in the pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs. A significantly higher percentage of CD4\u003csup\u003e+\u003c/sup\u003e T cells expressing CCR6, a regulator of migration and function of T\u003csub\u003eH17\u003c/sub\u003e cells was observed in BAL cells of cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eH) compared to LTBI and cART na\u0026iuml;ve RMs at necropsy. Similarly, we observed a significantly higher percentage of CD4\u003csup\u003e+\u003c/sup\u003e T cells co-expressing CXCR3 and CCR6 in cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs compared to LTBI and cART na\u0026iuml;ve RMs, in both, BAL and peripheral blood cells (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eI and \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eJ). Additionally, cART\u0026thinsp;+\u0026thinsp;3HP treated RMs harbored a significantly higher percentage of CXCR3\u003csup\u003e+\u003c/sup\u003eCCR6\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells (T\u003csub\u003eH1*\u003c/sub\u003e) in local and peripheral compartments compared to cART treated RMs (Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eI and \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eJ). These findings align with our previous observation that higher frequencies of CD4\u003csup\u003e+\u003c/sup\u003e T cells co-expressing CXCR3 and CCR6 associate with bacterial control in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. It has been previously reported that T\u003csub\u003eH1*\u003c/sub\u003e subset is the most frequent \u003cem\u003eMtb\u003c/em\u003e-specific T cell subset in the lungs of latent TB donors and that their numbers are increased when compared to healthy subjects [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The higher percentage of CXCR3\u003csup\u003e+\u003c/sup\u003eCCR6\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells in local and peripheral compartments could also be attributed to cART mediated control of viral replication as CXCR3\u003csup\u003e+\u003c/sup\u003eCCR6\u003csup\u003e+\u003c/sup\u003e cells are known to be preferential targets of HIV/SIV infection [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Further, a reduction in this cell subset could be attributed to higher rates of LTBI reactivation. Thus, treatment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs with cART\u0026thinsp;+\u0026thinsp;3HP increases migration of T\u003csub\u003eH17\u003c/sub\u003e and T\u003csub\u003eH1*\u003c/sub\u003e cells into pulmonary compartment compared to cART na\u0026iuml;ve RMs.\u003c/p\u003e \u003cp\u003e \u003cem\u003ePoor recovery of effector memory T cells by cART\u0026thinsp;+\u0026thinsp;3HP in Mtb/SIV co-infected RMs.\u003c/em\u003e \u003c/p\u003e \u003cp\u003eTo investigate functional immune reconstitution by cART\u0026thinsp;+\u0026thinsp;3HP in pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs, we further immunophenotyped the partially replenished CD4\u003csup\u003e+\u003c/sup\u003e T cells into central memory (CD28\u003csup\u003e+\u003c/sup\u003e/CD95\u003csup\u003e+\u003c/sup\u003e) (CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e) and effector memory (CD28\u003csup\u003e\u0026minus;\u003c/sup\u003e/CD95\u003csup\u003e+\u003c/sup\u003e) T cells (CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e) (Supplementary Fig.\u0026nbsp;2). SIV co-infection of latent \u003cem\u003eMtb\u003c/em\u003e infection caused a significant increase in percentage of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e in BAL at week 11 (peak viremia prior to cART\u0026thinsp;+\u0026thinsp;3HP treatment) (\u003cem\u003eP\u0026thinsp;\u0026lt;\u0026thinsp;0.0001\u003c/em\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA; Supplementary Fig.\u0026nbsp;3A). The increased percentage of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e persisted during and till end of the 12 week-long concurrent cART\u0026thinsp;+\u0026thinsp;3HP treatment. On the contrary, a significant decline occurred in the frequency of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e in BAL at peak viremia which marginally increased at end of 12 weeks cART\u0026thinsp;+\u0026thinsp;3HP treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB; Supplementary Fig.\u0026nbsp;3A). However, the percentage of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e at necropsy was significantly lesser than that seen in LTBI phase of the study (week 3 post \u003cem\u003eMtb\u003c/em\u003e-infection) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.002\u003c/em\u003e). These findings align with our previous observation that cART treatment fails to replenish the depleted CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e in BAL and lung of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Immunophenotyping of BAL CD8\u003csup\u003e+\u003c/sup\u003e T cells into CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e and CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e showed a significant increase (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.01\u003c/em\u003e) in percentage of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e at peak viremia (week 11 post-\u003cem\u003eMtb\u003c/em\u003e infection or 2 weeks post SIV co-infection). This increase was mitigated by cART\u0026thinsp;+\u0026thinsp;3HP as seen by marginally reduced percentage at necropsy (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.01\u003c/em\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC; Supplementary Fig.\u0026nbsp;3B). No significant change was observed in percentage of CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e in BAL at weeks 3, 11 and 24 (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD; Supplementary Fig.\u0026nbsp;3B) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.2\u003c/em\u003e). Thus, cART\u0026thinsp;+\u0026thinsp;3HP expands the CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u0026thinsp;+\u0026thinsp;T\u003csub\u003eCM\u003c/sub\u003e but is unable to replenish the CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e in pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe further compared the restoration of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e and CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e in BAL and lung of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with cART or cART\u0026thinsp;+\u0026thinsp;3HP (Figs.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE-\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eL). Despite similar percentage of CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL at necropsy, there was a significantly higher percentage (\u003cem\u003eP\u0026thinsp;\u0026lt;\u0026thinsp;0.0001\u003c/em\u003e) of CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs compared to cART treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). No significant difference was observed in lung CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF), BAL CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eG) and lung CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eH) between cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. Similar to CD4\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e, cART\u0026thinsp;+\u0026thinsp;3HP RMs exhibited significantly higher (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.009\u003c/em\u003e) percentage of CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e in BAL (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eI) with a concurrent decrease in CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e (P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eK) compared to cART treated RMs. However, there was no significant difference between lung CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eCM\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eJ) and CD8\u003csup\u003e+\u003c/sup\u003eT\u003csub\u003eEM\u003c/sub\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eL) in cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. Overall, there were dynamic changes in the memory phenotype of CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u003csup\u003e+\u003c/sup\u003e T cells in BAL compared to lung in cART and cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. BAL is a critical resource to study longitudinal changes in pulmonary immune response and has been shown to be useful to evaluate local response to therapy [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cem\u003ecART\u0026thinsp;+\u0026thinsp;3HP increases Mtb-specific T\u003c/em\u003e \u003csub\u003e \u003cem\u003eH1\u003c/em\u003e \u003c/sub\u003e \u003cem\u003e/T\u003c/em\u003e \u003csub\u003e \u003cem\u003eH17\u003c/em\u003e \u003c/sub\u003e \u003cem\u003eresponse in pulmonary compartment of Mtb/SIV co-infected RMs.\u003c/em\u003e\u003c/p\u003e \u003cp\u003eBAL samples were collected from study RMs at weeks 5, 11 and necropsy post \u003cem\u003eMtb\u003c/em\u003e infection using standard operating procedures by the veterinarian. Single cell suspensions were prepared as per the lab standardized protocol [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. All \u003cem\u003eMtb\u003c/em\u003e-specific responses were background corrected (Supplementary Fig.\u0026nbsp;5). BAL cells were stimulated \u003cem\u003eex vivo\u003c/em\u003e with \u003cem\u003eMtb\u003c/em\u003e-specific antigens, ESAT-6/CFP-10 and \u003cem\u003eMtb\u003c/em\u003e Cell Wall Fraction (\u003cem\u003eMtb\u003c/em\u003e CW) for 16 h and stained with flow cytometry antibodies to detect IFNg, TNFa, and IL-17. A significantly higher percentage of IFNg expressing \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells was seen in BAL of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs at end of treatment when stimulated with ESAT-6/CFP-10 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.04\u003c/em\u003e) and \u003cem\u003eMtb\u003c/em\u003e CW (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.009\u003c/em\u003e) compared to cART treated RMs. We hypothesize that cART\u0026thinsp;+\u0026thinsp;3HP treatment effectively control bacteria thus enhancing production of protective IFNg by \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells in pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. In contrast to IFNg, cART\u0026thinsp;+\u0026thinsp;3HP treatment resulted in a significantly lower percentage of \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells to produce TNFa in response to stimulation with either ESAT-6/CFP-10 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.03\u003c/em\u003e) or \u003cem\u003eMtb\u003c/em\u003e CW (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.009\u003c/em\u003e) compared to cART treated RMs. It has been reported previously that T-cell derived TNFa is essential for sustained protection during chronic \u003cem\u003eMtb\u003c/em\u003e infection [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] and that TNFa can promote proliferation of effector T cells resulting in increased immunogenicity [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. It has been demonstrated that antigen-specific expression of TNFa in the absence of IFNg on CD4\u003csup\u003e+\u003c/sup\u003e T cells in \u003cem\u003eMtb\u003c/em\u003e-infected patients strongly correlates with the potential to develop active TB, while the opposite phenotype is supportive of latent infection [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Our results therefore suggest that concurrent cART\u0026thinsp;+\u0026thinsp;3HP treatment results in the clearance of bacterial infection. Thus, concurrent treatment with cART\u0026thinsp;+\u0026thinsp;3HP does not result in increased production of \u003cem\u003eMtb\u003c/em\u003e-specific TNFa which in turn has a detrimental impact on effector function needed for sustained protection. Similar to IFNg, a significant increase in IL-17\u003csup\u003e+\u003c/sup\u003eCD4\u003csup\u003e+\u003c/sup\u003e T cells was observed in BAL of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs when stimulated with ESAT-6/CFP-10 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.01\u003c/em\u003e) and \u003cem\u003eMtb\u003c/em\u003e CW (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF) (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.005\u003c/em\u003e) compared to cART treated RMs. The trends were similar in lung with significantly higher percentage of CD4\u003csup\u003e+\u003c/sup\u003eT cells expressing IFNg (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.04\u003c/em\u003e) and IL-17 (\u003cem\u003eP\u0026thinsp;=\u0026thinsp;0.01\u003c/em\u003e) when stimulated with ESAT-6/CFP-10 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG) or \u003cem\u003eMtb\u003c/em\u003e CW (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eH) compared to cART treated RMs. While the role of T\u003csub\u003eH1\u003c/sub\u003e cells is clearly associated with protection in \u003cem\u003eMtb\u003c/em\u003e infection through IFNg production, the role of T\u003csub\u003eH17\u003c/sub\u003e cells is complex and is associated with tissue damage on one hand and anti-inflammatory response on the other hand. However, our findings align with the recent studies that show that \u003cem\u003eMtb\u003c/em\u003e-responsive IL-17- producing CD4\u003csup\u003e+\u003c/sup\u003e T cells are preserved in humans with LTBI with HIV-ART and that IL-17 producing CD4\u003csup\u003e+\u003c/sup\u003e T cells constitute the dominant response to \u003cem\u003eMtb\u003c/em\u003e antigen [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Moreover, we did not observe an increase in levels of pro-inflammatory cytokines, IL-6 and IP-10 in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs compared to cART treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eI). Overall, there is an increased T\u003csub\u003eH1\u003c/sub\u003e/T\u003csub\u003eH17\u003c/sub\u003e \u003cem\u003eMtb\u003c/em\u003e-specific response in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs that associates with protection but also has the potential to be pathological. In contrast we observed a decreased \u003cem\u003eMtb\u003c/em\u003e-specific TNFa response after concurrent treatment that could have detrimental impact on long term protection.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo better understand immune responses after concurrent cART\u0026thinsp;+\u0026thinsp;3HP treatment relative to cART-treatment, we assessed transcriptional profiles of lung cells collected at necropsy from \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected, cART or cART\u0026thinsp;+\u0026thinsp;3HP treated RMs by RNA sequencing (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eJ). \u003cem\u003eMtb\u003c/em\u003e is known to manipulate cell death pathways to evade host immunity, thereby protecting the bacilli from antibiotics, and allowing dissemination when timing is appropriate [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e].Gene terms associated with cell death, apoptosis, death receptor signaling, and necrosis were highly enriched amongst induced genes from the lungs of cART\u0026thinsp;+\u0026thinsp;3HP treated, compared to cART treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eJ). The increased expression of apoptosis-related genes could also be attributed to presence of antibiotics (isoniazid and rifapentine) that are known to cause oxidative damage in host cells, leading to increased apoptosis in addition to \u003cem\u003eMtb\u003c/em\u003e control [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. An increased expression of Type I IFN genes, such as IFNA2, IFNA1/IFNA13 was seen in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs compared to cART treated RMs (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eJ). The role of Type I IFN in TB is ambiguous. Both human and animal studies show evidence for the role of Type I IFN in \u003cem\u003eMtb\u003c/em\u003e expansion and disease pathogenesis [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Murine data particularly suggests that Type I IFN signaling promotes TB progression. Our own data from RMs suggests that pDC expressing Type I IFN associate with TB progression [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. A human blood transcriptional signature also largely comprised of Type I IFN response genes was described in TB patients [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e] and validated in macaques with TB [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. We have previously shown the enrichment of the Type I IFN signatures among the lymphoid cell clusters from the lungs of \u003cem\u003eMtb\u003c/em\u003e-infected mice [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. Together, these results suggest a pathological role for Type I IFN in TB. Thus, our finding of an increased Type I IFN signature aligns with previously reported transcriptional signatures in human and NHP experiments [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e] and suggests that while clinical disease is controlled by concurrent therapy, these animals continue to harbor molecular signatures associated with TB pathology and immune activation in the lung.\u003c/p\u003e \u003cp\u003e \u003cem\u003eSingle cell transcriptomic signature in pulmonary compartment of Mtb/SIV co-infected RMs\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eWe further investigated the transcriptional changes at single cell level in the pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with cART\u0026thinsp;+\u0026thinsp;3HP. We collected BAL at four critical time points from the same RMs during the study period; week 5 (represents the asymptomatic phase of \u003cem\u003eMtb\u003c/em\u003e infection), week 11 (represents 2 weeks post-SIV co-infection), week 13 (represents post-SIV co-infection and 4 weeks of cART treatment) and necropsy (study endpoint after 12 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment) (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA; Supplementary Fig.\u0026nbsp;6A, 6B). Using this experimental design, we were able to track the early transcriptomic changes in defined populations of cells at four different stages of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection. This negates the need for LTBI- and cART-na\u0026iuml;ve controls since they are represented by week 5 and week 11 timepoints in this study. All samples passed quality control in terms of cell quality (fraction reads in cells) and sequencing after which they were run on 10x chromium controller (Supplementary Table\u0026nbsp;1; Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC). Uniformed Manifold Approximation and Projection (UMAP) clustering identified 14 transcriptionally distinct cell clusters across all samples that can be broadly classified into lymphoid, myeloid and non-lymphoid, non-myeloid (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD, Supplementary Fig.\u0026nbsp;7A, 7B). Lymphoid clusters include C3 (CD4\u003csup\u003e+\u003c/sup\u003e memory T cells; \u003cem\u003eADAM23\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCAMK4\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD96\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCLEC2D\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eITK\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C6 (CD8 T cells; \u003cem\u003eCCR5\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD3D\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD3E\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD8A\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD8B\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eITM2A\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, C10 (NK cells; \u003cem\u003eNCAM1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eEOMES\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eGNLY\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eGZMA+, KLRB1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eHOPX\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C11 (B cells; \u003cem\u003eAFF3\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eAKAP2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eBLK\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD19\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD79A\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCNR2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCR2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eEBF1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e); Myeloid clusters include C0 (M2 macrophages; \u003cem\u003eMRC1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eALDH2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eAPOE\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eARL11\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD63\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD14\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eGSTO1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eRAB13\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eDNASE2B\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C1 (M1 macrophages; \u003cem\u003eIL-6+, IL-8+, SLC11A1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C4 (Monocytes; \u003cem\u003eCD14\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD163\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD68\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C5 (Neutrophils; \u003cem\u003eABHD2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eANO2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCACNA1D\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCACNB4\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eHAL\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eMCTP1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eMITF\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eTCF7L2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C7 (mDC; \u003cem\u003eCD1A\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCLIC2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eDSE\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eFLT3\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eEMP1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eP2RY6\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C9 (Granulocytes; \u003cem\u003eFCGR3\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eFPR1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eMNDA\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCSF3R\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C12 (Basophils; \u003cem\u003eCD63\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eENPP3\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), and C13 (Mast cells; \u003cem\u003eCD117\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD203c\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD63\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e). Non lymphoid non myeloid clusters include C2 (Ciliated cells; \u003cem\u003eSTK11\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eMARK3\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e), C8 (Endothelial cells; \u003cem\u003eFOXJ1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eDNAH5\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eTEKT1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e) and C14 (mesenchymal stromal cells; \u003cem\u003eCD44\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e, \u003cem\u003eCD79A\u003c/em\u003e\u003csup\u003e\u003cem\u003e+\u003c/em\u003e\u003c/sup\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe total number of transcripts (nFeature_RNA) and molecules (nCount_RNA) detected within each cell increased in early phase of SIV co-infection compared to LTBI phase (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF). Cells were filtered to detect genes within the range of 10-8000 to remove extremely low and high counts. The plot shows the distribution of detected gene levels of cells, and the colored shapes represent the distribution density (Figs.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF). The nFeature_RNA and nCount_RNA remained at higher levels at the end of cART\u0026thinsp;+\u0026thinsp;3HP treatment (necropsy time point) compared to LTBI phase of study (wk 5 time point). Based on published signature gene list, we analyzed T\u003csub\u003eH1\u003c/sub\u003e (\u003cem\u003eTBX21, IFNG, TNF, LTA, IL18RAP, BHLHE40, STAT1\u003c/em\u003e), T\u003csub\u003eH2\u003c/sub\u003e (\u003cem\u003eIL-4, IL-5, IL-6, IL-10, IL-13, KLF4, TCR\u003c/em\u003e) and T\u003csub\u003eH17\u003c/sub\u003e (\u003cem\u003eCCR6, RORA, RORC, IRF4, STAT3, IL23R, IL22\u003c/em\u003e) associated transcriptional changes in lymphoid (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA) and myeloid (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB) clusters at the pre-determined time points in BAL of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected, cART\u0026thinsp;+\u0026thinsp;3HP treated RMs (Supplementary Fig.\u0026nbsp;8). Relative to the LTBI phase time point (wk 5), an increased expression of genes \u003cem\u003eBHLHE40, STAT1, RORA, STAT3, KLF6\u003c/em\u003e was observed in lymphoid clusters and myeloid clusters at end of treatment with cART\u0026thinsp;+\u0026thinsp;3HP (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA, \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;9). IL23R was expressed at higher levels at all time points in CD4\u003csup\u003e+\u003c/sup\u003e memory T cell and CD8\u003csup\u003e+\u003c/sup\u003e T cell clusters. CD8\u003csup\u003e+\u003c/sup\u003e T cell cluster showed increased expression of activation marker genes; \u003cem\u003eKLRD1, CCL5, GZMB, GZMH, CTLA4, ICOS, LAG3\u003c/em\u003e. However, it is to be noted that not all T\u003csub\u003eH1\u003c/sub\u003e and T\u003csub\u003eH17\u003c/sub\u003e associated genes were up regulated in lymphoid and myeloid clusters post cART\u0026thinsp;+\u0026thinsp;3HP treatment. We did not observe an increased expression of \u003cem\u003eIL2\u003c/em\u003e, \u003cem\u003eTBX21, IFNG, TNF, LTA, IL18RAP, IL22, RORC, IRF4, CCR6\u003c/em\u003e at necropsy (end of cART\u0026thinsp;+\u0026thinsp;3HP) compared to wk 5 post \u003cem\u003eMtb\u003c/em\u003e infection (LTBI phase) (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA, \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;9). Negligible expression of T\u003csub\u003eH2\u003c/sub\u003e-associated genes was observed at all time points in both lymphoid and myeloid clusters (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA, \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;9) except for high expression of KLF4 in myeloid clusters. Additionally, there was a high expression of LAG3, an exhaustion marker, and CD38, an immune activation marker in CD8\u003csup\u003e+\u003c/sup\u003e T cell cluster post SIV co-infection at wk 11 and at end of cART\u0026thinsp;+\u0026thinsp;3HP treatment at necropsy. Overall, we hypothesize that cART\u0026thinsp;+\u0026thinsp;3HP mediates the increased T\u003csub\u003eH1\u003c/sub\u003e/T\u003csub\u003eH17\u003c/sub\u003e response in pulmonary compartment through increased expression of \u003cem\u003eBHLHE40, STAT1, RORA\u003c/em\u003e and \u003cem\u003eSTAT3\u003c/em\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eWe report here for the first time the impact of WHO-recommended cART\u0026thinsp;+\u0026thinsp;3HP treatment regimen on LTBI reactivation in \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected rhesus macaques in the presence of cART. As such, our results provide unprecedented, novel insights into the host response to co-infection and concurrent treatment. 3HP combines high dose isoniazid and rifapentine and is a once weekly, 12-week therapy taken orally. In humans, 3HP is associated with significantly lower hepatotoxicity and higher rates of completion than isoniazid preventive treatment [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. It is important to note that 3HP is a recommended regimen to treat LTBI and prevent TB in persons living with HIV. Recent clinical trials (Dolphin-study) have shown that for people starting anti-HIV treatment, combining dolutegravir containing cART with 3HP TB preventive treatment is safe and works efficiently in tandem [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e] with high rates of viral suppression. Modeling concurrent cART\u0026thinsp;+\u0026thinsp;3HP in \u003cem\u003eMtb\u003c/em\u003e/HIV co-infection using a relevant animal model, such as NHPs, provides an invaluable tool to investigate the impact on local immune responses. The NHP model is attractive for studying human \u003cem\u003eMtb\u003c/em\u003e infection and for performing preclinical studies on treatment regimens as it recapitulates key aspects of human \u003cem\u003eMtb\u003c/em\u003e infection states and TB disease [\u003cspan additionalcitationids=\"CR49 CR50\" citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. Our group has previously shown that earlier initiation of cART suppresses the virus, partially reconstitutes CD4\u003csup\u003e+\u003c/sup\u003e T cells but fails to control inflammation and immune activation [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. We have also shown that administration of 3HP failed to sterilize bacteria in the lung of latently infected RMs with 2 of the 6 RMs showing culturable \u003cem\u003eMtb\u003c/em\u003e in the lungs (~\u0026thinsp;3 logs), 4 to 5 weeks post-SIV co-infection [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. In this study, we sought to determine if concurrent cART\u0026thinsp;+\u0026thinsp;3HP therapy initiated at early stages of co-infection better controls immune dysfunction in pulmonary compartment compared to cART.\u003c/p\u003e \u003cp\u003eAdministration of concurrent cART\u0026thinsp;+\u0026thinsp;3HP improved the clinical and microbiological attributes of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection compared to cART na\u0026iuml;ve or cART treated RMs. RMs were trained to take 3HP orally mimicking humans. As seen in the DOLPHIN study, our model demonstrated that co-administration of dolutegravir with 3HP was safe, well-tolerated and did not require any dose-adjustment of dolutegravir. Initiation of cART and 3HP at 2 weeks post \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection sterilized bacterial burden in lung of 5 out of 6 RMs and completely prevented dissemination to extra-pulmonary organs in all 6 RMs. There was a significant reduction in percent lung involvement in pathology in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs with visibly fewer granulomas compared to cART na\u0026iuml;ve or cART-treated RMs. The few granulomas observed at end of cART\u0026thinsp;+\u0026thinsp;3HP treatment were characterized as an equal mix of non-necrotizing and caseous type. 18F-FDG PET/CT scans revealed a significant reduction in number of lesions post treatment with cART\u0026thinsp;+\u0026thinsp;3HP but not in uptake of 18F-FDG in the few lesions that remained at ned of treatment. Taken together, cART\u0026thinsp;+\u0026thinsp;3HP treatment exerts bacterial and viral control, thereby improving the health status of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs during the study period. However, cART\u0026thinsp;+\u0026thinsp;3HP treated RMs continued to harbor granulomas that have the potential to release infectious bacilli and exhibit increased 18F-FDG uptake associated with inflammation.\u003c/p\u003e \u003cp\u003eWe next investigated immune reconstitution in the pulmonary compartment of RMs treated with cART\u0026thinsp;+\u0026thinsp;3HP compared to LTBI, cART na\u0026iuml;ve and cART-treated RMs. We have previously shown that cART is unable to reconstitute CD4\u003csup\u003e+\u003c/sup\u003e T cells in the lung tissue to the levels seen in LTBI and that the reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells are dysfunctional for \u003cem\u003eMtb\u003c/em\u003e-specific response [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Concurrent administration of cART and 3HP did not further improve the frequency of reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells in lung of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs compared to cART only treated RMs. The reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL and lung of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs exhibited an increased frequency of activated and inflamed phenotype compared to LTBI RMs. Activated CD4\u003csup\u003e+\u003c/sup\u003e T cell phenotype associates with high risk for TB progression. Our model therefore demonstrates that SIV-induced activation of pulmonary CD4\u003csup\u003e+\u003c/sup\u003e T cells is not ameliorated by cART\u0026thinsp;+\u0026thinsp;3HP. A majority of reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells appeared to be central memory phenotype. On the contrary, there was a significant reduction in the effector memory CD4\u003csup\u003e+\u003c/sup\u003e T cells population in pulmonary compartment post SIV co-infection that cART\u0026thinsp;+\u0026thinsp;3HP did not alleviate as was also seen in cART treated RMs. CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e cells are critical for host protection to subsequent antigen encounter. The effector memory CD4\u003csup\u003e+\u003c/sup\u003e T cells can produce early effector cytokines such as IFNg and TNFa that help activate other cell types such as CD8\u003csup\u003e+\u003c/sup\u003e T cells or they can directly kill the infected cells. It is feasible that reduced bacterial burden results in reduced antigen presentation which can cause a reduced frequency of CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e cell in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. However, chronic \u003cem\u003eMtb\u003c/em\u003e infection such as a latent TB infection is known to elicit effector memory phenotype in CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u003csup\u003e+\u003c/sup\u003e T cells [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Our model recapitulates this phenotype as is seen by \u0026gt;\u0026thinsp;10% CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e in BAL collected from the same RM during LTBI phase that reduces to less than 3% post SIV co-infection. Clearly, the presence of CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e associates with an immune balance seen in LTBI in our model and a decrease in the frequency of this cell type contributes to immune dysfunction that cART\u0026thinsp;+\u0026thinsp;3HP fails to mitigate.\u003c/p\u003e \u003cp\u003eWe next determined the percentage and functionality of \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells in pulmonary compartment of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs treated with cART\u0026thinsp;+\u0026thinsp;3HP compared to cART. We performed \u003cem\u003eex vivo\u003c/em\u003e stimulation of BAL cells isolated at week 5 (represents the asymptomatic phase of \u003cem\u003eMtb\u003c/em\u003e infection), week 11 (represents 2 weeks post-SIV co-infection), and necropsy (after 12 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment) with ESAT-6/CFP-10 and \u003cem\u003eMtb\u003c/em\u003e CW. Upon 12 weeks of cART\u0026thinsp;+\u0026thinsp;3HP treatment, an increased percentage of IFNg and IL-17 producing \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells was seen in BAL and lung. Similar to what has been reported in humans, it is feasible that a majority of these T\u003csub\u003eH1\u003c/sub\u003e/T\u003csub\u003eH17\u003c/sub\u003e cytokine producing cells in BAL and lung are of central memory phenotype since CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eCM\u003c/sub\u003e were the dominant cell type observed in pulmonary compartment at end of cART\u0026thinsp;+\u0026thinsp;3HP treatment [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. On the contrary, a lesser percentage of TNFa- producing \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells was observed at the end of cART\u0026thinsp;+\u0026thinsp;3HP treatment compared to cART treated RMs. TNFa is required for granuloma organization and inhibition of TNFa through TNFa inhibitors result in TB reactivation [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. Hence, the skewed reconstitution of \u003cem\u003eMtb\u003c/em\u003e-specific response consisting of an increased IFNg and IL-17 response but a defective TNFa response could prove detrimental in long-term protection, altered granuloma formation and dissemination of disease.\u003c/p\u003e \u003cp\u003eBulk RNA sequencing of lung tissue collected at necropsy from cART\u0026thinsp;+\u0026thinsp;3HP treated RMs showed increased type I IFN response-associated genes; \u0026ldquo;\u003cem\u003eInterferon signaling\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eIFNA2\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eIFNA1/IFNA13\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eifnar\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003einterferon alpha\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eIRF9\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eIRF1\u003c/em\u003e\u0026rdquo; and apoptosis genes; \u0026ldquo;\u003cem\u003eApoptosis\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eApoptosis of epithelial cells\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003ecell death of progenitor cells\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003ecell death of germ cells\u003c/em\u003e\u0026rdquo;, \u0026ldquo;\u003cem\u003eApoptosis of hematopoietic cells\u003c/em\u003e\u0026rdquo; compared to cART treated RMs. Type I IFN are critical in host defense to viruses. However, there is a growing body of literature that describes the detrimental impact of type I IFN in \u003cem\u003eMtb\u003c/em\u003e infection [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. In humans, type I IFN is associated with loss of control and progression to TB disease [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e]. Recently, type I IFN was shown to play a role in \u003cem\u003eMtb\u003c/em\u003e-induced macrophage cell death that leads to release of bacilli from dead macrophages and dissemination. Previously, it was shown that the signaling pathways involved with type I IFN are involved in apoptosis [\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e] that explains the concomitant increase in expression of genes associated with apoptosis in cART\u0026thinsp;+\u0026thinsp;3HP treated RMs. Overall, RMs treated with cART\u0026thinsp;+\u0026thinsp;3HP present a distinct transcriptomic signature that associates with immune cell death. A deeper analysis of immunological recovery at the single cell level confirmed increased expression of genes associated with immune control of \u003cem\u003eMtb\u003c/em\u003e including, CD4\u003csup\u003e+\u003c/sup\u003e memory T cells, CD8\u003csup\u003e+\u003c/sup\u003e T, NK cells, B cells, M1/M2 macrophages, granulocytes and epithelial cells. Concurrent with the flow cytometry data, scRNAseq showed an increased expression of certain T\u003csub\u003eH1\u003c/sub\u003e and T\u003csub\u003eH17\u003c/sub\u003e-associated genes in lymphoid clusters at end of cART\u0026thinsp;+\u0026thinsp;3HP treatment. CD8\u003csup\u003e+\u003c/sup\u003e T cell cluster was characterized by an activated signature with substantially higher cytotoxic function-associated gene expression compared to CD4\u003csup\u003e+\u003c/sup\u003e memory T cells, NK and B cells. One possibility could be that this increased cytotoxic gene signature in CD8\u003csup\u003e+\u003c/sup\u003e T cell cluster associates with the increased apoptotic signature seen in bulk RNAseq since release of cytotoxic molecules by CD8\u003csup\u003e+\u003c/sup\u003e T cells is known to cause apoptosis of target cells [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e]. In humans on cART, increased expression of immune activation marker, CD38 on CD8\u003csup\u003e+\u003c/sup\u003e T cells during chronic HIV infection associates with the inability to proliferate and increased exhaustion. Overall, it is important to note that while cART\u0026thinsp;+\u0026thinsp;3HP effectively controls the virus and the bacilli, there is disproportionate reconstitution of memory subsets, levels of activation and exhaustion markers as well as their functional capacity.\u003c/p\u003e \u003cp\u003eThere are some limitations to this study. Since functional restoration of CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u003csup\u003e+\u003c/sup\u003e T cells is a gradual process in humans, our study, with a window of ~\u0026thinsp;3 months post-treatment, may not recapitulate these settings exactly. We necropsied the RMs at the end of 12-week cART\u0026thinsp;+\u0026thinsp;3HP treatment to match time points with previous cohorts. To study long-term immune reconstitution by cART\u0026thinsp;+\u0026thinsp;3HP, we are now planning future studies with extended time to necropsy post treatment completion. Another caveat is that the model may not provide a full physiological recapitulation of human \u003cem\u003eMtb\u003c/em\u003e/HIV co-infection, because RMs are exposed to a supraphysiological dose of SIV. Not all humans on cART are likely to exhibit treatment failure and progression to TB reactivation. However, \u003cem\u003eMtb\u003c/em\u003e/HIV co-infected individuals on cART remain\u0026thinsp;~\u0026thinsp;10- fold more likely to reactivate than HIV-na\u0026iuml;ve people with LTBI [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e]. Humans likely develop LTBI with a substantially lower infectious dose of \u003cem\u003eMtb\u003c/em\u003e (1\u0026ndash;2 CFU) than we use to infect RMs (~\u0026thinsp;10\u0026ndash;15 CFU \u003cem\u003eMtb\u003c/em\u003e CDC1551). RMs infected with the CDC1551 dose/strain combination exhibit control of \u003cem\u003eMtb\u003c/em\u003e infection akin to human LTBI, yet the dose is higher than the physiologically relevant human infectious dose. Hence, our results are indicative of the worst outcomes in co-infected humans. We infect the RMs through aerosol, the natural route of infection, mimicking humans. \u003cem\u003eMtb\u003c/em\u003e strain, CDC1551 allows for the development of a human TB model resulting in a latent to chronic rather than active TB disease [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. CDC1551 has also been shown to induce a protective immune response despite being similar in virulence to other lab strains [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e]. Thus, our model allows for an in-depth analysis of the clinical and immunological response in the lung to cART\u0026thinsp;+\u0026thinsp;3HP, which is possible only in a handful of research institutions world-wide. We are currently however, engaged in performing experiments with samples from human cohorts to validate our results.\u003c/p\u003e \u003cp\u003eIn conclusion, while concurrent cART and 3HP effectively suppress the virus and bacteria, the quality of immune reconstitution in the pulmonary compartment remains significantly sub-optimal. cART\u0026thinsp;+\u0026thinsp;3HP treatment increases the T\u003csub\u003eH1\u003c/sub\u003e/T\u003csub\u003eH17\u003c/sub\u003e response in lung but there is incomplete restoration of protective, CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e and replenished \u003cem\u003eMtb\u003c/em\u003e-specific CD4\u003csup\u003e+\u003c/sup\u003e T cells are skewed in their ability to produce TNFa. Though concurrent therapy improves pathological burden, there is increased 18F-FDG uptake in the few lesions that remain despite treatment. Further, transcript analysis of lung and BAL showed an increased expression of CD38, an immune activation marker on CD8\u003csup\u003e+\u003c/sup\u003e T cells, as well as of apoptotic signature characteristic of cell death. Our results clearly show that despite the mitigation of co-infection, chronic immune activation persists in the lungs of concurrently treated NHPs. Targeting the host immune response via a host-directed immunotherapy provides an opportunity to augment immunity during the short-window of acute HIV-1 co-infection of \u003cem\u003eMtb.\u003c/em\u003e Future studies should perform testing of safety and efficacy of novel host-directed therapies such as IL-21-IgFc fusion protein administration or use of IDO-1 inhibitors concurrent to standardized therapies in tissues and organs like the lung, that are impossible to access in humans. This is critical for the development of an immune-based intervention along with cART and anti-TB therapy to control dysregulated immune responses generated during early events of HIV co-infection of LTBI and provide long-term immune reconstitution.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cem\u003eAnimal infection\u003c/em\u003e. This study included macaque data from completed studies [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. A total of 18 specific pathogen free Indian-origin rhesus macaques (\u003cem\u003eMacaca mulatta\u003c/em\u003e) were infected with a low dose of approximately 10 CFU \u003cem\u003eM. tuberculosis\u003c/em\u003e CDC1551 (BEI Resources, catalog NR13649) via aerosol as described before [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan additionalcitationids=\"CR67\" citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e] (Supplementary Table\u0026nbsp;2). TST was performed at weeks 3 and 5 post TB infection to confirm infection. All the RMs were monitored for CRP, percent body weight and body temperature weekly through the study period. 14 of the LTBI RMs were then co-infected with 300 TCID\u003csub\u003e50\u003c/sub\u003e SIVmac\u003csub\u003e239\u003c/sub\u003e via the intravenous route 9 weeks post-TB infection [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e] (provided by the Preston Marx Laboratory, TNPRC, Covington, Louisiana, USA). All the procedures were conducted a board-certified veterinary clinician. The remaining 4 RMs served as LTBI controls for the study. The viral infection was confirmed through plasma viral loads via reverse transcription quantitative PCR (RT-qPCR). Upon confirmation of SIV infection, the 18 RMs were then divided into 3 groups: the first group of 8 RMs served as co-infected controls with no cART administration; the second group of 4 RMs were started on cART at 2 weeks post-SIV co-infection or 11 weeks post TB infection (cART at peak viremia) and the third group of 6 RMs started cART\u0026thinsp;+\u0026thinsp;3HP at 2 weeks post-SIV co-infection once weekly for 12 weeks. All the RMs in cART-naive group had to be euthanized within 2\u0026ndash;4 weeks of cART treatment due to clinical signs of TB reactivation. The RMs in the cART group were euthanized after 9 weeks of cART treatment while the RMs in cART\u0026thinsp;+\u0026thinsp;3HP group were euthanized at end of 12-week treatment at week 24.\u003c/p\u003e \u003cp\u003e \u003cem\u003ecART\u0026thinsp;+\u0026thinsp;3HP regimen.\u003c/em\u003e Co-infected RMs received a drug regimen consisting of 20 mg/kg of (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA, tenofovir, Gilead Sciences), 30 mg/kg of 2\u0026rsquo;, 3\u0026rsquo;-dideoxy-5-fluoro-3\u0026rsquo;-thiacytidine (FTC, emtricitabine, Gilead Sciences) and 2.5 mg/mL of the integrase inhibitor, DTG, Dolutegravir (ViiV Healthcare). The drugs were administered daily via subcutaneous injection of a cocktail of these three drugs in the vehicle kleptose at previously published doses [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Co-infected RMs also received a weekly oral dose of 15mg/kg isoniazid and 15 mg/kg rifapentine for 12 weeks beginning week 12 after aerosol infection up to week 23 post-TB infection. Oral intake was monitored by veterinary staff to ensure consumption.\u003c/p\u003e \u003cp\u003e \u003cem\u003ePositron emission tomography-computed tomography (PET/CT) imaging.\u003c/em\u003e Longitudinal CT and PET/CT scans were performed using MEDISO\u0026rsquo;s LFER150 PET-CT scanner at 3\u0026ndash;6 week intervals, starting from week 6 post-\u003cem\u003eMtb\u003c/em\u003e infection with the last scan prior to necropsy [\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e]. Briefly, we performed 18F-fluorodeoxyglucose (FDG) PET/CT scans for each anesthetized RM using the breath-hold technique. RMs were anesthetized and intubated under supervision of a board-certified veterinarian as per approved IACUC protocols. All the RMs received an intravenous injection of 1 mCi per kg of body weight dose of 18F-FDG [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e], procured from Cardinal Health radiopharmacy. The single field of view (FOV) and/or double FOV lung CT scans were performed using breath-hold as described [\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e]. PET scans were acquired after completion of the 40\u0026ndash;50 min FDG uptake period. Images were visualized using Interview Fusion 3.03 (Mediso) and reconstructed using Nucline NanoScan LFER 1.07 (Mediso) with parameters as described [\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e]. The lung segmentation, volumetric and SUV analysis was performed using Vivoquant 4.0 (Invicro, USA) [\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cem\u003eViral load and bacterial burden measurement\u003c/em\u003e. Bacterial burden in BAL was measured throughout the study period as previously described [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Viable \u003cem\u003eMtb\u003c/em\u003e burden was also measured at necropsy in BAL, lung, spleen, bronchial lymph node and individual granulomas collected at necropsy [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. Viral loads in acellular BAL supernatant and plasma were determined by RT-qPCR at peak viremia (2 weeks post-SIV or 11 weeks post TB-infection), week 13, week 15 post-\u003cem\u003eMtb\u003c/em\u003e infection and at necropsy. The measurements were performed by NIAID, DAIDS, Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development). A lower limit of 100 copies/ sample was set for quantification of SIV copies in this assay.\u003c/p\u003e \u003cp\u003e \u003cem\u003eHigh parameter flow cytometry\u003c/em\u003e. High parameter flow cytometry was performed on BAL cells at pre-infection, pre-SIV (wk 3, 5), post-SIV, pre-cART (wk 11), post-cART (wk 20 or necropsy) and post-cART\u0026thinsp;+\u0026thinsp;3HP (wk 24 or necropsy). Lung, bronchial lymph nodes and granulomas were harvested at necropsy and processed as described earlier [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. The single cells prepared were then stained with surface and intracellular markers to study various cell phenotypes (Supplementary Table\u0026nbsp;3). The freshly collected BAL cells were stimulated \u003cem\u003eex vivo\u003c/em\u003e with \u003cem\u003eMtb\u003c/em\u003e-specific antigens, ESAT-6/CFP-10 and \u003cem\u003eMtb\u003c/em\u003e Cell Wall Fraction (BEI Resources, 10 \u0026micro;g/mL) for a total of 16 h. Brefeldin A (0.5 \u0026micro;g/mL, SIGMA) was added 2 h after the onset of stimulation. After stimulation, the cells were stained with LIVE/DEAD fixable Near-IR stain (ThermoFisher) and stained subsequently with the surface antibodies: CD4-PerCP-Cy5.5 (BD Biosciences), CD8-APC (BD Biosciences), CD3-AlexaFlour 700 (BD Biosciences), CD95-BV421 (BD Biosciences), CD28-PECy7 (BD Biosciences) and CD45-BUV395 (BD Biosciences). Cells were then fixed, permeabilized and stained with intracellular antibodies: IFNγ - APC-Cy7 (Biolegend), IL-17-BV605 (Biolegend) and TNFα - BV650 (Biolegend). Cells were washed, suspended in BD stabilizing fixative buffer and acquired on BD FACS Symphony flow cytometer. Analysis was performed using FlowJo (v10.6.1) using previously published gating strategy [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cem\u003eGross pathology\u003c/em\u003e. The animals were euthanized for necropsy and lung lobes, spleen, liver, bronchial lymph nodes were collected. All the tissues were weighed at the time of collection. Tissues were fixed in 10% neutral-buffered formalin, paraffin embedded, sectioned at 5 \u0026micro;m thickness and stained with hematoxylin and eosin using standard methods. Lung tissues were collected stereologically at necropsy and stereology scores were prepared on percentage lung affected by a board-certified veterinary pathologist.\u003c/p\u003e \u003cp\u003e \u003cem\u003eImmunohistochemistry staining\u003c/em\u003e. Fluorescent immunohistochemistry was performed on formalin-fixed, paraffin-embedded lung and bronchial lymph node tissues as previously described [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e, \u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e]. The stained slides were scanned in the Axio Scan Z1 and the images were analyzed using HALO software.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eStudy Approval\u003c/strong\u003e \u003cp\u003e All infected animals were housed under Animal Biosafety Level 3 facilities at the Southwest National Primate Research Center, where they were treated according to the standards recommended by AAALAC International and the NIH guide for the Care and Use of Laboratory Animals. The study procedures were approved by the Animal Care and Use Committee of the Texas Biomedical Research Institute.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eQuality control for frozen BAL cells\u003c/em\u003e. Prior to running the BAL cells on 10x Genomics platform, the cells were analyzed for viability using i) automated cell countess, ii) manual counts using Trypan Blue and iii) microscopic evaluation. Briefly, cells were thawed on ice. 100 \u0026micro;L of cells was washed once in 1 mL warmed 1x phosphate buffered saline (PBS) (Gibco), centrifuged, and resuspended in 1 mL of 1x PBS. Cells were mixed in 1:1 ratio with Trypan blue and counted in automated countess as well by hemocytometer (Supplementary Table\u0026nbsp;1). Cellular morphology, including shape and size was determined using a standard bright field light microscope. Institutional approved protocols were applied when removing samples from BSL3.\u003c/p\u003e \u003cp\u003e \u003cem\u003eSingle cell RNA Library generation and sequencing\u003c/em\u003e. BAL cell suspensions were loaded onto Chromium instrument (10x Genomics) to generate single-cell beads in emulsion. Single-cell RNA-seq libraries were then prepared using Single Cell 3\u0026rsquo; Gel bead and library kit version 3.1 (10\u0026times; Genomics). Single cell barcoded cDNA libraries were quantified and sequenced on an Illumina NovaSeq 6000. Read lengths were 28bd for read 1, 10bp for index 1, 10bp for index 2, and 100bp for read 2. Cells were sequenced to about 50,000 reads per cell.\u003c/p\u003e \u003cp\u003e \u003cem\u003eSingle cell data analysis\u003c/em\u003e. Cell ranger Single Cell Software suite (V7.0.1) from 10x was used to perform sample demultiplexing and generate fastq files. Resulting fastq files were aligned against reference genome mmul10 (Genebank, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov/datasets/genome/GCF_003339765.1/\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_003339765.1/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) with cellranger count. The targeted cell recovery per sample was set to 10,000 cells. The cellranger counting results for 16 samples were further integrated and analyzed by R software with package Seurat (V4.4.0). The data matrix for each sample was read by Read10X and filtered by removing cells which have more than 8000 detected genes in each sample. All 16 samples data were merged, normalized with method \u0026ldquo;LogNormalize\u0026rdquo;, and most variable genes were detected by the FindVariableFeatures function with nfeatures 2000. Anchor genes were selected by SelectIntegrationFeatures and FindIntegrationAnchors, and further applied to integrated dataset by IntegrateData. The integrated data were scaled by ScaleData and principal component analysis [\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e] was performed by RunPCA with npcs\u0026thinsp;=\u0026thinsp;30. To visualize the data, the TSNE dimensionality reduction was performed using the first 20 PCA. Data clustering was run by FindNeighbors (pca 20) and FindClusters (resolution 0.2). Basic marker genes for each cluster were firstly identified using FindAllMarkers function in Seurat R package by (logFC.threshold\u0026thinsp;\u0026gt;\u0026thinsp;0.25, minPct\u0026thinsp;\u0026gt;\u0026thinsp;0.1), then the marker genes with different cut-off were further studied and evaluated. Heatmaps were created by Seurat Package using the mean expression of markers in each cluster per time point.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConflicts of Interest Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have declared that no conflict of interest exists.\u003c/p\u003e\u003cp\u003eAvailability of data\u003c/p\u003e\n\u003cp\u003eThe single cell RNAseq raw and processed files are available at NCBI Gene Expression Omnibus and the accession number is\u0026nbsp;xxxxx.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eStatistics\u003c/em\u003e. Statistical analysis was performed using an unpaired Student\u0026rsquo;s t test, 1- or 2- way ANOVA with Sidak\u0026rsquo;s or Tukey\u0026rsquo;s correction as applicable in GraphPad Prism (version 8.4.1). \u0026nbsp;A \u003cem\u003eP\u0026nbsp;\u003c/em\u003evalue of \u0026lt;0.05 was considered as statistically significant. *\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05; **\u003cem\u003eP\u003c/em\u003e \u0026lt;0.01; ***\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001; ****\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.0001. Data are represented as Mean \u003cu\u003e+\u0026nbsp;\u003c/u\u003eSEM. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by\u0026nbsp;National Institutes of Health (NIH) investigator-\u0026nbsp;AI111943, AI123047,\u0026nbsp;OD031898 and AI170148, and institutional- grants\u0026nbsp;OD010442, AI168439, AI161943,\u0026nbsp;OD028732, OD032443 and CPRIT Core Facility Award (RP220662).\u0026nbsp;SIVmac\u003csub\u003e239\u003c/sub\u003e was graciously provided by Drs Preston Marx and Nick Manness, Tulane National Primate Research Center. SIV viral load assays were performed by the Nonhuman Primate Core Virology Laboratory for AIDS Research and Development, Division of AIDS, NIAID. PMPA and FTC were provided by Gilead Sciences and DTG was provided by Viiv Healthcare.\u0026nbsp;Data was generated in the Genome Sequencing Facility, which is supported by UT Health San Antonio, CA054174.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRS, JR, DK designed the study. RS and BS performed sample collection and processing. VS, EJ performed macaque necropsies and pathology studies. SHU was the attending veterinarian for the study. XA performed the PET/CT and related analysis. RS, ZL, YZ and DK performed the data analysis. ZL performed quality control of BAL cells, 10x scRNA-seq and NGS workflow. SAK, JR helped RS and DK in writing of the manuscript.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWong, N.S., et al., \u003cem\u003eA longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients\u003c/em\u003e. Sci Rep, 2019. 9(1): p. 10093.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDravid, A., et al., \u003cem\u003eIncidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India\u003c/em\u003e. BMC Infect Dis, 2019. 19(1): p. 714.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhmed, A., et al., \u003cem\u003eIncidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study\u003c/em\u003e. BMJ Open, 2018. 8(2): p. e016961.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu, E., et al., \u003cem\u003eTuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy\u003c/em\u003e. Aids, 2015. 29(11): p. 1391\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLawn, S.D., et al., \u003cem\u003eBurden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control\u003c/em\u003e. Aids, 2006. 20(12): p. 1605\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuthar, A.B., et al., \u003cem\u003eAntiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis\u003c/em\u003e. PLoS Med, 2012. 9(7): p. e1001270.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdhikari, N., et al., \u003cem\u003ePrevalence and associated risk factors for tuberculosis among people living with HIV in Nepal\u003c/em\u003e. PLoS One, 2022. 17(1): p. e0262720.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDanel, C., et al., \u003cem\u003eA Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa\u003c/em\u003e. N Engl J Med, 2015. 373(9): p. 808\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBadje, A., et al., \u003cem\u003eEffect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial\u003c/em\u003e. Lancet Glob Health, 2017. 5(11): p. e1080-e1089.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRangaka, M.X., et al., \u003cem\u003eIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial\u003c/em\u003e. Lancet, 2014. 384(9944): p. 682\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSemitala, F.C., et al., \u003cem\u003eCompletion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial\u003c/em\u003e. PLoS Med, 2021. 18(12): p. e1003875.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChaisson, L.H., et al., \u003cem\u003eViral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine\u003c/em\u003e. Aids, 2023. 37(7): p. 1097\u0026ndash;1101.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharan, R., et al., \u003cem\u003eIsoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs\u003c/em\u003e. J Clin Invest, 2022. 132(18).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBucsan, A.N., et al., \u003cem\u003eMechanisms of reactivation of latent tuberculosis infection due to SIV co-infection\u003c/em\u003e. J Clin Invest, 2019.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharan, R., et al., \u003cem\u003eAntiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model\u003c/em\u003e. J Clin Invest, 2022. 132(3).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuroda, M.J., et al., \u003cem\u003eHigh Turnover of Tissue Macrophages Contributes to Tuberculosis Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques\u003c/em\u003e. J Infect Dis, 2018. 217(12): p. 1865\u0026ndash;1874.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eForeman, T.W., et al., \u003cem\u003eCD4\u0026thinsp;+\u0026thinsp;T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection\u003c/em\u003e. Proc Natl Acad Sci U S A, 2016. 113(38): p. E5636-44.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharan, R., et al., \u003cem\u003eChronic Immune Activation in TB/HIV Co-infection\u003c/em\u003e. Trends Microbiol, 2020. 28(8): p. 619\u0026ndash;632.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGanatra, S.R., et al., \u003cem\u003eAnti-retroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV co-infection model\u003c/em\u003e. J Clin Invest, 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGanatra, S.R., et al., \u003cem\u003eAntiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model\u003c/em\u003e. J Clin Invest, 2020. 130(10): p. 5171\u0026ndash;5179.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMacatangay, B.J.C., et al., \u003cem\u003eT cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy\u003c/em\u003e. Aids, 2020. 34(1): p. 15\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDay, C.L., et al., \u003cem\u003ePD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression\u003c/em\u003e. Nature, 2006. 443(7109): p. 350\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShanmugasundaram, U., et al., \u003cem\u003ePulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment\u003c/em\u003e. JCI Insight, 2020. 5(14).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArlehamn, C.L., et al., \u003cem\u003eTranscriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features\u003c/em\u003e. J Immunol, 2014. 193(6): p. 2931\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGosselin, A., et al., \u003cem\u003ePeripheral blood CCR4\u0026thinsp;+\u0026thinsp;CCR6\u0026thinsp;+\u0026thinsp;and CXCR3\u0026thinsp;+\u0026thinsp;CCR6\u0026thinsp;+\u0026thinsp;CD4\u0026thinsp;+\u0026thinsp;T cells are highly permissive to HIV-1 infection\u003c/em\u003e. J Immunol, 2010. 184(3): p. 1604\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDawson, R., et al., \u003cem\u003eImmunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis\u003c/em\u003e. PLoS One, 2009. 4(9): p. e6984.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchwander, S. and K. Dheda, \u003cem\u003eHuman lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection\u003c/em\u003e. Am J Respir Crit Care Med, 2011. 183(6): p. 696\u0026ndash;707.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMehra, S., et al., \u003cem\u003eReactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus\u003c/em\u003e. J Med Primatol, 2011. 40(4): p. 233\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, G., et al., \u003cem\u003eAnti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8\u0026thinsp;+\u0026thinsp;T effector levels in Han Chinese pulmonary TB patients\u003c/em\u003e. Microbes Infect, 2020. 22(3): p. 119\u0026ndash;126.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAllie, N., et al., \u003cem\u003eProminent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection\u003c/em\u003e. Sci Rep, 2013. 3: p. 1809.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlsen, A., et al., \u003cem\u003eTargeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines\u003c/em\u003e. mBio, 2016. 7(3).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMehta, A.K., D.T. Gracias, and M. Croft, \u003cem\u003eTNF activity and T cells\u003c/em\u003e. Cytokine, 2018. 101: p. 14\u0026ndash;18.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePollock, K.M., et al., \u003cem\u003eT-cell immunophenotyping distinguishes active from latent tuberculosis\u003c/em\u003e. J Infect Dis, 2013. 208(6): p. 952\u0026ndash;68.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarari, A., et al., \u003cem\u003eDominant TNF-α\u0026thinsp;+\u0026thinsp;Mycobacterium tuberculosis-specific CD4\u0026thinsp;+\u0026thinsp;T cell responses discriminate between latent infection and active disease\u003c/em\u003e. Nat Med, 2011. 17(3): p. 372\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOgongo, P., et al., \u003cem\u003eHigh-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL17 against M. tuberculosis antigen\u003c/em\u003e. bioRxiv, 2024.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAfriyie-Asante, A., et al., \u003cem\u003eMycobacterium tuberculosis Exploits Focal Adhesion Kinase to Induce Necrotic Cell Death and Inhibit Reactive Oxygen Species Production\u003c/em\u003e. Front Immunol, 2021. 12: p. 742370.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePark, H.E., et al., \u003cem\u003eUnderstanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?\u003c/em\u003e Front Immunol, 2021. 12: p. 703060.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoreira-Teixeira, L., et al., \u003cem\u003eType I interferons in tuberculosis: Foe and occasionally friend\u003c/em\u003e. J Exp Med, 2018. 215(5): p. 1273\u0026ndash;1285.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEsaulova, E., et al., \u003cem\u003eThe immune landscape in tuberculosis reveals populations linked to disease and latency\u003c/em\u003e. Cell Host Microbe, 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScott, N.R., et al., \u003cem\u003eS100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis\u003c/em\u003e. J Clin Invest, 2020. 130(6): p. 3098\u0026ndash;3112.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerry, M.P., et al., \u003cem\u003eAn interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis\u003c/em\u003e. Nature, 2010. 466(7309): p. 973\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhmed, M., et al., \u003cem\u003eImmune correlates of tuberculosis disease and risk translate across species\u003c/em\u003e. Sci Transl Med, 2020. 12(528).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAkter, S., et al., \u003cem\u003eMycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes\u003c/em\u003e. Cell Rep, 2022. 39(12): p. 110983.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEsaulova, E., et al., \u003cem\u003eThe immune landscape in tuberculosis reveals populations linked to disease and latency\u003c/em\u003e. Cell Host Microbe, 2021. 29(2): p. 165\u0026ndash;178.e8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMartinson, N.A., et al., \u003cem\u003eNew regimens to prevent tuberculosis in adults with HIV infection\u003c/em\u003e. N Engl J Med, 2011. 365(1): p. 11\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSterling, T.R., et al., \u003cem\u003eThree months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons\u003c/em\u003e. Aids, 2016. 30(10): p. 1607\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDooley, K.E., et al., \u003cem\u003eOnce-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial\u003c/em\u003e. Lancet HIV, 2020. 7(6): p. e401-e409.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaushal, D., et al., \u003cem\u003eThe non-human primate model of tuberculosis\u003c/em\u003e. J Med Primatol, 2012. 41(3): p. 191\u0026ndash;201.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScanga, C.A. and J.L. Flynn, \u003cem\u003eModeling tuberculosis in nonhuman primates\u003c/em\u003e. Cold Spring Harb Perspect Med, 2014. 4(12): p. a018564.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFlynn, J.L., et al., \u003cem\u003eImmunology studies in non-human primate models of tuberculosis\u003c/em\u003e. Immunol Rev, 2015. 264(1): p. 60\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGideon, H.P., et al., \u003cem\u003eMultimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control\u003c/em\u003e. Immunity, 2022. 55(5): p. 827\u0026ndash;846.e10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCounoupas, C. and J.A. Triccas, \u003cem\u003eThe generation of T-cell memory to protect against tuberculosis\u003c/em\u003e. Immunol Cell Biol, 2019. 97(7): p. 656\u0026ndash;663.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGehad, A., et al., \u003cem\u003eA primary role for human central memory cells in tissue immunosurveillance\u003c/em\u003e. Blood Adv, 2018. 2(3): p. 292\u0026ndash;298.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRobert, M. and P. Miossec, \u003cem\u003eReactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor\u003c/em\u003e. Cell Mol Immunol, 2021. 18(7): p. 1644\u0026ndash;1651.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMundra, A., et al., \u003cem\u003ePathogenicity of Type I Interferons in Mycobacterium tuberculosis\u003c/em\u003e. Int J Mol Sci, 2023. 24(4).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcNab, F., et al., \u003cem\u003eType I interferons in infectious disease\u003c/em\u003e. Nat Rev Immunol, 2015. 15(2): p. 87\u0026ndash;103.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMayer-Barber, K.D. and B. Yan, \u003cem\u003eClash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses\u003c/em\u003e. Cell Mol Immunol, 2017. 14(1): p. 22\u0026ndash;35.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoreira-Teixeira, L., et al., \u003cem\u003eType I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis\u003c/em\u003e. Nat Commun, 2020. 11(1): p. 5566.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu, G., et al., \u003cem\u003eInsights into battles between Mycobacterium tuberculosis and macrophages\u003c/em\u003e. Protein Cell, 2014. 5(10): p. 728\u0026ndash;36.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eApelbaum, A., et al., \u003cem\u003eType I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands\u003c/em\u003e. Mol Cell Biol, 2013. 33(4): p. 800\u0026ndash;14.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrezzemolo, T., et al., \u003cem\u003eFunctional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis\u003c/em\u003e. Front Immunol, 2014. 5: p. 180.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLawn, S.D., A. Gupta, and R. Wood, \u003cem\u003eAssessing the impact of prevalent tuberculosis on mortality among antiretroviral treatment initiators: accurate tuberculosis diagnosis is essential.\u003c/em\u003e Aids, 2012. 26(13): p. 1730-1; author reply 1728-9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGupta, A., et al., \u003cem\u003eTuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community\u003c/em\u003e. PLoS One, 2012. 7(3): p. e34156.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManca, C., et al., \u003cem\u003eMycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates\u003c/em\u003e. J Immunol, 1999. 162(11): p. 6740\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBucşan, A.N., et al., \u003cem\u003eMechanisms of reactivation of latent tuberculosis infection due to SIV coinfection\u003c/em\u003e. J Clin Invest, 2019. 129(12): p. 5254\u0026ndash;5260.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMehra, S., et al., \u003cem\u003eThe Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs\u003c/em\u003e. J Infect Dis, 2012. 205(8): p. 1203\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMehra, S., et al., \u003cem\u003eGranuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis\u003c/em\u003e. J Infect Dis, 2013. 207(7): p. 1115\u0026ndash;27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaushal, D., et al., \u003cem\u003eMucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis\u003c/em\u003e. Nat Commun, 2015. 6: p. 8533.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSingh, D.K., et al., \u003cem\u003eResponses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets\u003c/em\u003e. Nat Microbiol, 2021. 6(1): p. 73\u0026ndash;86.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStammes, M.A., et al., \u003cem\u003eRecommendations for Standardizing Thorax PET-CT in Non-Human Primates by Recent Experience from Macaque Studies\u003c/em\u003e. Animals (Basel), 2021. 11(1).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMattila, J.T., et al., \u003cem\u003ePositron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells\u003c/em\u003e. J Immunol, 2017. 199(2): p. 806\u0026ndash;815.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSakai, S., et al., \u003cem\u003eFunctional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates\u003c/em\u003e. Mucosal Immunol, 2021. 14(5): p. 1055\u0026ndash;1066.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, Q., et al., \u003cem\u003eA technique to simultaneously visualize virus-specific CD8\u0026thinsp;+\u0026thinsp;T cells and virus-infected cells in situ\u003c/em\u003e. J Vis Exp, 2009(30).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlexandrov, L.B., et al., \u003cem\u003eThe repertoire of mutational signatures in human cancer\u003c/em\u003e. Nature, 2020. 578(7793): p. 94\u0026ndash;101.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"cART, 3HP, TB/SIV co-infection, LTBI, reactivation","lastPublishedDoi":"10.21203/rs.3.rs-4908400/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4908400/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe majority of Human Immunodeficiency Virus (HIV) negative individuals exposed to \u003cem\u003eMycobacterium tuberculosis\u003c/em\u003e (\u003cem\u003eMtb\u003c/em\u003e) control the bacillary infection as latent TB infection (LTBI). Co-infection with HIV, however, drastically increases the risk to progression to tuberculosis (TB) disease. TB is therefore the leading cause of death in people living with HIV (PLWH) globally. Combinatorial antiretroviral therapy (cART) is the cornerstone of HIV care in humans and reduces the risk of reactivation of LTBI. However, the immune control of \u003cem\u003eMtb\u003c/em\u003e infection is not fully restored by cART as indicated by higher incidence of TB in PLWH despite cART. In the macaque model of co-infection, skewed pulmonary CD4\u003csup\u003e+\u003c/sup\u003e T\u003csub\u003eEM\u003c/sub\u003e responses persist, and new TB lesions form despite cART treatment. We hypothesized that regimens that concurrently administer anti-TB therapy and cART would significantly reduce TB in co-infected macaques than cART alone, resulting in superior bacterial control, mitigation of persistent inflammation and lasting protective immunity. We studied components of TB immunity that remain impaired after cART in the lung compartment, versus those that are restored by concurrent 3 months of once weekly isoniazid and rifapentine (3HP) and cART in the rhesus macaque (RM) model of LTBI and Simian Immunodeficiency Virus (SIV) co-infection. Concurrent administration of cART\u0026thinsp;+\u0026thinsp;3HP did improve clinical and microbiological attributes of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infection compared to cART-na\u0026iuml;ve or -untreated RMs. While RMs in the cART\u0026thinsp;+\u0026thinsp;3HP group exhibited significantly lower granuloma volumes after treatment, they, however, continued to harbor caseous granulomas with increased FDG uptake. cART only partially restores the constitution of CD4\u0026thinsp;+\u0026thinsp;T cells to the lung compartment in co-infected macaques. Concurrent therapy did not further enhance the frequency of reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL and lung of \u003cem\u003eMtb\u003c/em\u003e/SIV co-infected RMs compared to cART, and treated animals continued to display incomplete reconstitution to the lung. Furthermore, the reconstituted CD4\u003csup\u003e+\u003c/sup\u003e T cells in BAL and lung of cART\u0026thinsp;+\u0026thinsp;3HP treated RMs exhibited an increased frequencies of activated, exhausted and inflamed phenotype compared to LTBI RMs. cART\u0026thinsp;+\u0026thinsp;3HP failed to restore the effector memory CD4\u003csup\u003e+\u003c/sup\u003e T cell population that was significantly reduced in pulmonary compartment post SIV co-infection. Concurrent therapy was associated with the induction of Type I IFN transcriptional signatures and led to increased \u003cem\u003eMtb\u003c/em\u003e-specific T\u003csub\u003eH1\u003c/sub\u003e/T\u003csub\u003eH17\u003c/sub\u003e responses correlated with protection, but decreased \u003cem\u003eMtb\u003c/em\u003e-specific TNFa responses, which could have a detrimental impact on long term protection. Our results suggest the mechanisms by which \u003cem\u003eMtb\u003c/em\u003e/HIV co-infected individuals remain at risk for progression due to subsequent infections or reactivation due of persisting defects in pulmonary T cell responses. By identifying lung-specific immune components in this model, it is possible to pinpoint the pathways that can be targeted for host-directed adjunctive therapies for TB/HIV co-infection.\u003c/p\u003e","manuscriptTitle":"Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-26 08:38:19","doi":"10.21203/rs.3.rs-4908400/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-communications","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"NCOMMS","sideBox":"Learn more about [Nature Communications](http://www.nature.com/ncomms/)","snPcode":"","submissionUrl":"https://mts-ncomms.nature.com/","title":"Nature Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Communications","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"22f0087e-7dec-4ddb-8de0-4d64f0c1d25f","owner":[],"postedDate":"August 26th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":36131329,"name":"Health sciences/Diseases/Infectious diseases/Tuberculosis"},{"id":36131330,"name":"Biological sciences/Immunology/Infectious diseases/HIV infections"}],"tags":[],"updatedAt":"2026-01-15T08:10:16+00:00","versionOfRecord":{"articleIdentity":"rs-4908400","link":"https://doi.org/10.1038/s41467-025-67188-4","journal":{"identity":"nature-communications","isVorOnly":false,"title":"Nature Communications"},"publishedOn":"2025-12-12 05:00:00","publishedOnDateReadable":"December 12th, 2025"},"versionCreatedAt":"2024-08-26 08:38:19","video":"","vorDoi":"10.1038/s41467-025-67188-4","vorDoiUrl":"https://doi.org/10.1038/s41467-025-67188-4","workflowStages":[]},"version":"v1","identity":"rs-4908400","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4908400","identity":"rs-4908400","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}